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Strategic Skills Needs in the Bio-medical Sector
Launched on 1st April 2008, the UK Commission for Employment and Skills is a key recommendation 
in Lord Leitch’s 2006 review of skills Prosperity for All in the Global Economy: World Class Skills. The 
UK Commission aims to raise UK prosperity and opportunity by improving employment and skills. 
Its ambition is to benefit individuals, employers, government and society by providing independent 
advice to the highest levels of the UK Government and Devolved Administrations on how improved 
employment and skills systems can help the UK become a world class leader in productivity, in 
employment and in having a fair and inclusive society.
Research and policy analysis plays a fundamental role in the work of the UK Commission and is 
central to its advisory function. In fulfilling this role, the Research and Policy Directorate of the UK 
Commission is charged with delivering a number of the core activities of the UK Commission and 
has a crucial role to play in:
• Assessing progress towards making the UK a world-class leader in employment and skills 
by 2020;
• Advising Ministers on the strategies and policies needed to increase employment, skills 
and productivity;
• Examining how employment and skills services can be improved to increase employment retention 
and progression, skills and productivities;
• Promoting employer investment in people and the better use of skills.
We will produce research of the highest quality to provide an authoritative evidence base; we will 
review best practice and offer policy innovations to the system; we will undertake international 
benchmarking and analysis and we will draw on panels of experts, in the UK and internationally, to 
inform our analysis.
Sharing the findings of our research and policy analysis and engaging with our audience is very 
important to the UK Commission. Our Evidence Reports are our chief means of reporting our detailed 
analytical work. Our other products include Summaries of these reports; Briefing Papers; Thinkpieces, 
seminars and an annual Research and Policy Convention. All our outputs are accessible in the 
Research and Policy pages at www.ukces.org.uk. 
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The Bio-Medical Sector
The aim of the study is to assess the strategic skill needs of the bio-medical sector.  This sector 
has been defined as the combination of the pharmaceutical, medical biotechnology, and medical 
technologies sectors; in other words, those industries which produce the drugs, therapies, and 
equipment for the health care system in the UK and abroad.
Because of major scientific breakthroughs over recent years which have the scope to radically improve 
the well being of the population - especially those currently suffering or at risk of chronic illness – the 
industry is very much seen as one with colossal future potential.  From an employment and skills 
perspective there are many uncertainties relating to the situation in England but, on balance, the 
outlook is an optimistic one.
England currently has an enviable position in the global market given the level of research and 
development activity which is concentrated in the country, especially around Cambridge and the 
corridor from the west of London and along the Thames Valley towards Oxford.  It also has a 
substantial manufacturing capacity to be found across the country but notably in the North West and 
South East.
Looking to the future, the key findings from the study reveal the following.
The Importance of the Bio-Medical Sector
• It an important sector for the national economy with respect to output and employment.  It is also 
a principal constituent of the knowledge economy, with the pharmaceutical sector not only being 
the largest investor in R&D in the country, but also at the forefront of global developments to bring 
about a major transformation in the treatment of illness in the 21st Century.
• The investment in R&D reflects the pharmaceutical industry’s strong demand for highly qualified 
scientists, engineers, and technologists, often qualified at postgraduate level with skills at the 
cutting edge of the latest scientific developments.  The industry has been able to articulate 
precisely the scientific skills it requires over the medium-term even though it is difficult to quantify 
the level of skills demand.
• Arguably, the level of technological change is such that skill demand will always outpace skills 
supply.  Of vital importance is the extent to which the supply-side can catch up with demand relative 
to that in other countries.  Collaboration between higher education (HE), the health service, and 
industry through clustering and networking appears to be the principal mechanism though skills 
supply has largely been developed to support scientific and technological advancement.
• England is a dominant player in the global pharmaceutical market, though this is not the case in 
the medical technologies sub-sector.  Much of the industry’s success has been dependent upon 
Executive Summary
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the rich supply of research scientists extant in the UK, and the relative strength of the UK higher 
education sector in subjects allied to the industry.  The relationship would appear to be mutually 
reinforcing with the capacity to attract highly skilled and qualified people from around the world.
Drivers of Change in the Bio-Medical Sector
• Forecasts of future employment and skill demand suggest that overall employment levels will 
remain more or less static.  But as mentioned above there a number of uncertainties – threats and 
opportunities - which the industry faces over the medium-term, including, amongst others:
 • the capacity of scientific breakthroughs to result in new products and therapies which willre 
 place those which are currently nearing the end of their patents;
	 • the demand for health care which results from demographic change (e.g. people living longer  
 with chronic conditions and the pressure this places on the health service); 
	 • environmental considerations (e.g. the need to reduce waste);
	 • constraints of health care expenditure (e.g. the need to constrain in some way the 
 almost infinite demands being made on national health care systems to provide the latest 
 treatments, and the need to develop treatments which might reduce health care costs – 
 such as telemedicine);
	 • consumer demand and expectations (e.g. the willingness of patients to pay for new treatments);
	 • globalisation and corporate strategic choice (e.g. the corporate decisions which are made 
 about where products are developed and manufactured to serve the global market).
• Technological change provides a number of opportunities for the industry, such as the development 
of the next generation of drugs which use biological rather than chemical processes.  These 
are generally considered positive for the industry’s development because they will generate a 
stream of new products and therapies.  Given England’s concentration of R&D activity, and the 
critical mass of research scientists in the country, it is well placed to retain its position as a pre-
eminent centre of innovation and product development.  But this cannot be taken for granted.  It is 
important that investment continues in R&D both within the sector and in the external R&D sector 
(i.e. HE) to maintain this position.
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Employment Levels
• The sector in England is estimated to employ around 95,000 people - and many of these people 
are occupied in skilled trades and machine processing jobs – with, in addition, a substantial 
number of people employed in the supply chain.  Compared to the sector’s position as a centre for 
innovation and product development, medium term prospects for employment in the manufacturing 
part are less clear.
• One version of the future sees mass production increasingly being transferred to lower cost 
countries as the leading companies look to cut their costs because of the increasing levels of 
investment required to successfully bring new products to market, and due to patents lapsing.
• More positively, as some drug treatments become more bespoke, requiring manufacture to 
exacting standards but in relatively small batches, this raises the prospect of niche production 
becoming important.  Hence employment growth amongst the niche producers may replace any 
loss from mass production being transferred elsewhere.
• Though overall employment numbers are unlikely to show much growth over the medium-
term with the numbers employed in each occupation, other than managers and professionals, 
showing a decline, the workforce is relatively aged which suggests that there will be substantial 
replacement demands across the occupational structure of the sector. The challenge here is to 
attract people, especially young people, into an industry which signals that the overall number of 
people it employs is in decline.  
Skill Demand and Supply
• As the foregoing has said, the future of the high-tech, knowledge intensive part of the industry 
is dependent upon the future supply of highly qualified scientists engineers and technologists. 
What is less clear is the extent to which the existence of a prestigious R&D sector is sufficient 
to safeguard manufacturing employment.  This would appear to be subject to both the strategic 
choices the principal companies in the sector make about where they want to locate production 
and the extent to which developments in the sector push manufacturing increasingly towards 
niche manufacture.
• Without doubt the manufacture of bio-medical products is dependent upon intermediate level 
skills – skilled trade workers and technicians.  Without a supply of these skills manufacturers are 
likely to face skill shortages which will impose constraints on production.  Manufacturing is also 
dependent upon management being well versed in the skills required to operate in the sector 
of the market into which they may find themselves migrating.  For example, in the case of the 
production of goods which are becoming increasingly commoditised, then skill sets may need to 
migrate to focus more than ever on keeping costs down (e.g. lean manufacture, etc.).
xi
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The Future
• Whilst there are considerable uncertainties attached to the future direction of the sector there are 
grounds for substantial optimism for this country because of the range of new treatments which 
are likely to come on stream over the medium-term.
• Often the debate is very much focused on the pharmaceutical sector, and with good cause too 
given the colossal scale of its R&D investments and its capacity to bring on line those drugs and 
therapies which will safeguard the well being of the population.  The medical technologies sub-
sector receives much less focus because it is relatively small with respect to output, R&D and 
employment, and is not so recognisably a world leader compared to either the USA or Germany.
• It is readily apparent that developments in health care will be dependent upon medical technologies 
and that there is, through the use of communication technologies, the potential for the convergence 
of drug therapies with medical technologies.  Future demand for medical technologies could be 
a major source of employment growth and skill demand which might provide a boost for the 
country’s engineering sector.  The demand here, in the first instance, is to equip engineering firms 
with the strategic skills which will allow them to diversify into the medical market and negotiate 
access to health care markets both here and abroad.  In the second instance, skill demand relates 
to manual engineering skills at Levels 2 and 3 which will be required to meet future demand. 
Engineering is a sector which has encountered relatively high skill shortages over the recent past 
and the types of skilled people they require are subject to considerable replacement demands 
over the medium term.
• Overall, the assessment provided in this report suggests that there is significant employment 
potential in the sector which will be dependent upon skills supply being adequate at a number 
of levels.  In pharmaceuticals the country is in an enviable position as a world leader and with 
respect to medical technologies there is considerable scope for the country’s engineering sector 
to take advantage of an expanding market.
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1.1 Introduction
Maintenance of advanced economy status is dependent upon being at the forefront of the latest 
technological advances.  The ancient Greek and Roman economies were built upon the development 
and application of technologies considered to be advanced for the time, similarly the strength of 
many west European economies is rooted in their ability to have harnessed the potential of the 
technologies which gave rise to the Industrial Revolution.  At various junctures in history there have 
been technological breakthroughs which have changed the face of industry: water-power, steam, 
electricity, internal combustion engines, micro-processors, etc.  Bio-medical technologies may well 
be the new paradigm for the 21st century.  This very much classifies bio-medical technologies as a 
state-of-the-art, cutting edge industry dependent upon the skills at the very highest levels of scientific 
and engineering know-how.   But there is a need to temper this view a little.  While this description 
of the industry is accurate for at least part of it, there are other important sub-sectors which produce 
the everyday goods and services required by the population, such as the standard medicines and 
equipment upon which the health service is dependent for the treatment of large numbers of patients, 
which are important sources of output and employment.  Producing these goods is often a profitable 
one for the organisations concerned but their skill needs will be different from those at the cutting 
edge of bio-medical technologies.  From an employment and skills perspective both are important: 
one provides many jobs now, the other the potential to create many jobs in the future.
New Industry, New Jobs (BIS, 2009) proposal for targeted intervention by Government to foster 
growth in key industries mentions the life sciences and pharmaceuticals sector as one which has 
significant potential for growth.  As this report will highlight, Government through its funding of 
research and development in the higher education sector is already substantially involved in the 
bio-medical sector.  More directly, the Office for Life Sciences within the Department for Business 
Innovation and Skills was established in January 2009 to provide targeted intervention to help the 
sector realise its potential.  So the “new activism” that New Industry, New Jobs calls for is already 
extant, to some degree, through industry-higher education-health service collaborative relationships 
and a dedicated policy focus.  Of course, this is all relative and in a competitive global market the key 
question is whether these relationships are as effective as those found in other countries.
This report is concerned with skills.  Skills supply can be a constraint on output and employment growth 
where it is quantitatively or qualitatively mismatched with demand.  There is evidence, though now 
somewhat dated, that a failure to invest in skills development over the economic cycle can result in 
future skills shortages which, in turn, can exacerbate future economic downturns (Hogarth and Wilson, 
2002).  Analysis by Cogent and SEMTA, which this study draws upon, has highlighted the characteristics 
of skill demand for the sector and the extent to which skill demand has been, and is likely to be, satisfied 
(Cogent, 2006, 2009; SEMTA, 2006).  In a sector which is subject to relatively quick technological 
change, skills supply is always likely to lag behind skills demand hence the need to have as clear a 
view as possible of the emerging characteristics of skill demand.  This report looks at the drivers of skill 
demand across the sector as a whole – from the ultra high-tech activities to more everyday ones - and 
the issues this raises for the supply side.  As will become evident, the sector’s critical skill needs are 
multifaceted and range from doctoral level research scientists to intermediate level technicians.  
1 Introduction: Aims and objectives of the study
2Strategic Skills Needs in the Bio-medical Sector
1.2 Aims of the Study
The broad aims of the study are to:
i. develop an overview of the economic, social and technical drivers of change in the 
bio-medical sector with a demonstration of why the sector is so important to the economy;
ii. develop an in-depth analysis of global and national trends in skills and employment within the 
bio-medical sector; including skills insight and foresight and labour market impact.  This will give 
consideration to the priority skills within the sector;
iii. consider future strategic challenges and trends for the sector, outlining possible alternative sector 
scenarios and implications and consider how they impact on the labour market and skills.
The specific questions the study addresses are listed below.
• How is the sector/sub-sector of interest defined?  
• Why is the sector of particular economic importance?
• What are the current technological developments in the sector and how might these change 
in the future?
• What are the likely growth trends (of both output and employment) in the sector?
• What are the opportunities and risks associated with a particular growth sector?
• What are the current and future employment and skills implications of growth for the sector?
• Will change be quantitative (more/less of the same) or qualitative (i.e. see the emergence 
of new skills, the combination of skills sets, a new application of old skill sets, etc.?
• What is the spatial dimension to growth and skill needs: regional, national, European, global?
• What would be an appropriate response to the skills challenge in the chosen sector?
The study has been conducted through an analysis of various statistical sources, including the 
production of occupational employment projections derived from the Working Futures database, 
a literature review, and interviews with key stakeholders in the industry.
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There are three elements to the study:
i. a review of the literature;
ii. a review of available statistics and economic forecasts for key elements of the bio-medical sector;
iii. a series of interviews with key stakeholders (see Appendix 1).
1.3	 Defining	the	Sector
Defining the sector according to the Standard Industrial Classification (SIC) is not straightforward 
because the SIC is based on historically developed classifications and, at best, gives a partial 
coverage.  The categories of the SIC which appear to be most relevant are:
  24.4 Manufacture of pharmaceuticals, medicinal chemicals and botanical products
  24.41 Manufacture of basic pharmaceutical products
  24.42  Manufacture of pharmaceutical preparations
  24.42/1 Manufacture of medicaments
  24.42/2  Manufacture of non-medicaments
  33 Manufacture of Medical, Precision and Optical Instruments, Watches and Clocks
 33.1  Manufacture of medical and surgical equipment and orthopaedic appliances
 33.10  Manufacture of medical and surgical equipment and orthopaedic appliances
For convenience the sector is referred to as the bio-medical sector. It refers to those employers 
and employees who are engaged in the production of goods and services which are inputs to the 
health system.  The health system itself of course is also involved in the production of these goods 
and services but it is exceedingly difficult to measure this activity.  Research also shows that many 
companies in the bio-medical sector involved in the production of medical technologies tend to be 
involved in various other manufacturing activities as well.  Medical technologies or technologies, 
though a significant part of their output, are not their principal output and so they are not categorised 
as medical technology producers.  Again this affects the measurement of the sector.
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More conceptually the bio-medical sector can be defined as a combination of:
• Pharmaceuticals;
• Medical technologies; and
• Medical biotechnology.
Biotechnology refers to the use of biological systems, living organisms, to make or modify products 
and processes.  Its application is not limited to the bio-medical sector given that it has uses throughout 
industry and consequently it is not readily identifiable in industrial classifications.  From a conceptual 
perspective the sector is defined as pharmaceuticals plus medical technologies, and that part of 
the biotechnology sector concerned with medical applications.  As the next chapter will reveal, 
while mutually exclusive statistical information is available for the pharmaceuticals and medical 
technologies sub-sectors this is not so for biotechnology.  Data relating to medical biotechnology, 
where available, overlaps with pharmaceuticals and, to a lesser extent, with medical technologies 
such that there is a danger of double-counting.
As well as defining the sector according to the SIC, the sector can also be defined with reference to 
the technologies it uses.  The areas of technology are set out in the International Patent Classification 
(IPC)1, which broadly speaking fall under A61 (medical or veterinary science; hygiene).2 
1.4 Overarching Approach to the Study
At a generic level, future skill needs are usually seen to be driven by:
• innovation and technological change;
• demographic change;
• environmental change;
• legislation / regulation;
• changing patterns of consumer demand;
• globalisation.
1 http://www.wipo.int/classifications/ipc/ipc8/?lang=en.
2 This includes a wide range of sub-classes from high technology areas (e.g. various parts of A61B, diagnosis; surgery; identification) to areas of relatively 
low technology (e.g. various parts of A61K, preparations for medical, dental, or toilet purposes)
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In many respects the principal driver is innovation and technological change.  The industry is primarily 
concerned with problem solving – essentially how to stop people becoming ill or incapacitated and, 
if they are unfortunate enough to be so, to make them well again.  The levels of R&D expenditure in 
the sector are large by comparison with many other industries and the degree of technological and 
scientific progress over the past half century or so has been rapid.  Whilst demographic change, 
environmental change, and so forth are challenges which the industry needs to address, it is through 
the development of new products and processes that these challenges will turn into opportunities. 
Hence a considerable part of this report is given over to assessing the level of technological progress 
and how that might be optimised over the medium term.
Skill requirements, both strategic and tactical, stem from both the need to innovate and from the 
consequences of those innovations being introduced into the health system.  The study is not solely 
concerned with the latest, large-scale scientific and technological advances, such as stem cell 
research or new genetic therapies, but also a range of more commonplace developments which 
have the capacity to both aid well being and increase economic output and employment.  In the 
medical technologies sub-sector, for instance, there are many incremental technological advances 
which have considerable potential albeit in a less headline grabbing fashion.
1.5 Structure of the Report
The structure of the report is as follows.  Chapter 2 provides an indication of the sector’s scale in 
England and its importance to the economy.  Chapter 3 summarises the drivers of change.
Technological change is the principal driver of change in the sector and the emerging technological 
trends reflected in patenting activity, and their potential to affect skill levels, are outlined in Chapters 4.
Chapter 5 provides an assessment of future skill demand generally based on Working Futures data 
but also other assessments which provide a more detailed breakdown of skill needs.  Chapter 6 
considers the skills supply side and the factors which might be giving rise to reports of shortages for 
key skills.  In Chapter 7, the importance of clustering and networking is considered.  Finally Chapter 
8 provides a conclusion and highlights some of the issues germane to the skills policy debate. 
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2.1 The Structure of the Sector
Chapter 1 provided a brief description of the sector based on SIC and patent classifications.  In 
practice, the structure of the sector is much more complex than these classifications indicate.  In 
general, the sector as a whole overlaps with the health service (mainly the NHS) and higher education 
institutions (see Figure 2.1).  The NHS in many respects is the main consumer of the outputs of the 
bio-medical sector, but it is also engaged in the development of new products and processes.  Higher 
education institutions (HEIs) are also an important part of the sector in that they are engaged in the 
development of many new products and processes, sometimes in partnership but also on a sole 
basis.  The health service and HEIs are also competitors for skills in the sector.
Figure 2.1 Schematic Structure of the Bio-medical Sector
 
The study is concerned very much with the sector as defined at the core of Figure 2.1.  It needs, 
however, to be recognised that there are important forward and backward linkages to be considered. 
These can be important in employment terms; for example, the supply of intermediate goods for 
inclusion in the production of pharmaceuticals and medical technologies.  The forward and backward 
linkages are set out in Figure 2.2 simply to clarify the importance of the sector to other areas of 
activity in the economy.
 
2 The Importance of the Sector:  
 Output and Employment
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Technologies
Pharmaceuticals
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Figure 2.2 Forward and Backward Linkages to the Bio-medical Sector
2.2 The World Market
Statistical evidence is unable to fully capture the scale of activity of the sector as outlined in either 
Figure 2.1 or 2.2 above.  Instead there is a need to make-do with estimates produced for the 
pharmaceutical and medical technology sectors respectively.  Based on this evidence the market for 
bio-medical products is large.
Vfa estimates that in 2007 the output of pharmaceutical producers in the USA, Japan, and Europe 
amounted to Euro 352 billion (Vfa, 2009).  US producers accounted for a third of output (33 per cent) 
and the UK (7 per cent).  Over time there is relatively little change in the share of the market held by the 
major producers except for the decline in the share accounted for by Japan (see Figure 2.3).  Vfa notes 
that over time medium-sized European countries such as Ireland, Austria, Belgium and Switzerland 
have been able to expand the volume of their pharmaceutical production (Vfa, 2009). The implication 
of Figure 2.3 is that the UK has been able to maintain its share of the pharmaceutical market.
 
Supply of  
professional services 
(e.g. accountancy, 
marketing)
Bio-medical sector
Suppliers of 
intermediate products
Supply of scientific 
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laboratory testing, 
R&D)
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Figure 2.3 Share of Production in USA, Japan, and Europe, 1990 and 2007
Source: OECD, EFPIA, Pharmaceutical associations of the European countries, vfa; http://www.vfa.de/en/statistics/economy/
 
Estimates of the size of the medical technologies market are more difficult to obtain.  In 2004, the 
world market was estimated to be worth $169 billion (approximately £260 billion) with USA producers 
accounting for 43 per cent of the market, the EU 21 per cent, and Japan 15 per cent (AdvaMed, 
2004).  More recent data suggests that the medical technologies market is estimated to be worth 
£150-170bn worldwide with growth rates forecast at 10 per cent a year over the next five to six years, 
such that the market size will be worth a projected £300bn by 2015 (BIS/UKTI/DoH, 2009).  The US 
market is the largest at an estimated £70bn.
Growth in global demand for medical technologies is expected to be buoyant over the medium term 
as a consequence of demographic change and the emergence of increased demand from developing 
economies in, for example, Brazil, India, and China.  This is discussed in more detail below.  What 
is less clear at this point is the extent to which existing producers in the West will need to develop 
production facilities in markets they are serving, rather than relying upon exports, the nature of the 
production agreements they might develop with indigenous producers, and the extent to which they 
will be pressed into lowering prices (Hodson et al., 2008; Deloittes, 2009).  These developments 
seem inevitable; it is scale of these developments which is of interest, not whether they take place.
The latest Government report on the medical biotechnology sector indicates that the global medical 
biotechnology market is worth around £45-48bn, and experienced growth rates of more than 20 per 
cent a year between 2002 and 2007 which, the report notes, is more than double the rate for the 
pharmaceutical market.  The USA is estimated to account for around two thirds of the market (65 per 
cent of all sales) (BIS/UKTI/DoH, 2009).
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Because at least part of the sector has been identified as being capable of generating relatively high 
levels of output and employment growth over the medium-term, it has created intense competition 
from countries around the world which are all keen to steal a lead in developing a critical mass of 
activity.  Map 2.1, below, reveals where the critical mass of activity is currently in the biotechnology 
sub sector.  As can be identified from the map, there are few major industrial countries which have 
not developed a cluster of biotechnology activity, typically based around company – HEI collaboration 
and partnership.  It is also apparent that the UK, especially England, is well represented.
Map 2.1 Clusters of Activity in Biotechnology 
 
Source: Rinaldi (2006) p. 135
 
Note: Countries coloured in brown rank highly in the Growth Competitiveness Index 2004–2005, World Economic Forum. Black circles represent selected 
biotechnology and life-sciences clusters
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2.3 Output in the UK
The evidence suggests that the UK is one of the leading producers of bio-medical goods and 
services in the world.  This is especially so in pharmaceuticals and biotechnology.  In the latter 
(biotechnology) – though not all of this is medical related – the UK would appear to have the largest 
number of employees in Europe, and the second largest number of companies behind Germany 
(Critical I, 2006a).
The value of output in the bio-medical sector is difficult to measure for a number of reasons relating 
to how the sector is defined.  Based on measures of output for the pharmaceuticals sector, and an 
estimate of the output from the instrument engineering sector attributable to medical technologies, an 
approximate estimate of the value of output is £15,235 millions (2005 constant prices) – approximately 
1 per cent of total output (Cambridge Econometrics, 2009).  The trend in output is provided in Figures 
2.4a and 4.2b and reveals a relatively strong output growth, especially in pharmaceuticals, although 
output trends in this part of the industry are subject to a degree of fluctuation.
 
Figure 2.4a Output Trends in the Bio-Medical Sector in the UK, 1971-2020
  
 
Source: Cambridge Econometrics Database; own calculations
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Figure 2.4b Output Trends in the Bio-Medical Sector in the UK, 1971-2020 (annual 
percentage growth)
  
 
 
Source: Cambridge Econometrics Database; own calculations
The Medical Technologies Metrics series published by BERR (now part of BIS) provides a precise 
estimate of the value of output from the medical technologies sector (BERR, 2008a).  This suggests 
the sales turnover of UK manufacturers was around £5,000m in 2006 (see Figure 2.5).  The total 
market in the UK has an estimated value of £8,000m.  The data for 2006, also suggests that the 
value of exports (£4,528m) exceeded those of imports (£4,395m), but these data also highlight 
relatively high levels of trade between the UK and abroad.
Figure 2.5 Sales Turnover of UK Medical Technology Manufacturers  
 
 
Source: BERR Medical Technology Metrics Table 7, BERR, 2008a
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The data provided by the BERR database also indicates that UK production of medical technologies 
is relatively small compared to that in Germany (see Figure 2.6).
Figure 2.6 Production of Medical technologies in the EU,1999-2006
 
 
Source: BERR, 2008a, Indicator 17 derived from Europrom data 
2.4 R&D Expenditure
The R&D Scorecard produced by BIS demonstrates that the pharmaceutical and biotechnology 
sector is the largest investor in R&D in the UK.  A number of stylised facts reveal how significant the 
sector’s contribution is to innovation in the UK (BERR, 2008b, p.26):
• the pharmaceuticals and biotechnology sector was the largest contributor to R&D in both the top 
850 and the top 1400 UK companies in 2007;
• pharmaceuticals and biotechnology companies accounted for 37 per cent of the R&D spend of 
the top 850 companies; 
• eight of the top 25 R&D investors globally are pharmaceuticals companies: they include two firms 
with major UK based facilities, GlaxoSmithKline and Astra Zeneca; 
• GlaxoSmithKline and AstraZeneca dominate R&D spend in the UK pharmaceuticals sector.  They 
spent 89 per cent of the sector total, and 37 per cent of the UK850 spend; 
• R&D in the pharmaceuticals and biotechnology industry continues to grow more quickly than 
sales amongst the largest investors. 
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To some extent the figures above relate to the scale of the companies in the pharmaceuticals sector, 
but the R&D Scorecard also reveals that on measures of R&D activity, such as the ratio of R&D 
expenditure to sales, pharmaceutical and biotechnology companies stand out.  Eleven out of the top 
fifteen companies ranked by the ratio of sales to R&D expenditure are involved in the production of 
pharmaceuticals or health care equipment (see Table 2.1).
Table 2.1 Companies with the highest ratio of R&D expenditure to sales (2007)
Note:  * - foreign owned firm
Source:  BERR 2008b, Table 8, p.31
Company R&D as a 
proportion of 
sales (%)
R&D (£m) Growth in 
R&D over last 
year (%) 
Sector
Solexa (now Illumina Cambridge)* 1,768 14.8 60.8 Health care equipment & services 
Ark Therapeutics 1,301 14.6 12.4 Pharmaceuticals & biotechnology 
CeNeS Pharmaceuticals  
(now part of Paion, Germany) 
1,081 5.9 -19.6 Pharmaceuticals & biotechnology 
Paradigm Therapeutics (not Takeda 
Cambridge) (now part of Takeda 
Pharmaceutical, Japan)* 
697 7.1 24.9 Pharmaceuticals & biotechnology
Lombard Medical Technologies 632 6.4 33.1 Health care equipment & services 
MediGene* 591 4.3 -17.9 Pharmaceuticals & biotechnology 
ClearSpeed Technology 524 6.4 5.7 Technology hardware & 
equipment 
Celtic Pharma Development* 503 10.1 131.3 Pharmaceuticals & biotechnology 
Sosei R&D* 460 13.2 27.9 Pharmaceuticals & biotechnology 
Oxford Biomedica 307 22.1 13.4 Pharmaceuticals & biotechnology 
TIBCO Software* 303 2.9 209.2 Software & computer services 
Osmetech 295 2.8 -50.9 Pharmaceuticals & biotechnology 
Antonov 293 2.3 90.0 Automobiles & parts 
Summit 277 8.4 186.2 Pharmaceuticals & biotechnology 
Acambis 266 25.3 -31.6 Pharmaceuticals & biotechnology
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UKTI estimates that UK companies account for 40 per cent of all products in the pipeline by European 
public companies, and goes on to say: “ The country’s success in life sciences – with UK companies 
accounting for 45 per cent of new biotechnology drugs in late-stage clinical trials in Europe – is driven 
by its rich pool of talent and skills. Its world-class scientific institutions, impressive research base and 
track record in product development continue to attract and retain healthcare innovators.”3  
Strategically, the evidence base suggests that the UK is well placed to capture future gains in the 
medical biosciences field, because:
• there is relatively little regulation governing genetic research compared to other countries 
(e.g. stem cell research);
• a strong R&D base in both companies and higher education; and 
• a centralised healthcare system (the NHS).
In contrast to the pharmaceutical and biotechnology sector, R&D expenditure in the medical 
equipment sector is estimated to be around £150m (2007) (BERR, 2008a).
2.5 Overall Employment Levels
In the UK, the pharmaceutical industry employs around 73,000 people many in high level occupations.4 
BIS/UKTI/DoH (2009) estimates that around 24,000 people are employed in the medical biotechnology 
sub-sector in the UK, but it is likely that many of these people are already accounted for in the 
pharmaceutical sector’s employment total. The medical technologies sector is also an important source 
of employment.  The ABI estimates that around 40,000 people are employed in the sector in the UK, but 
the Labour Force Survey estimates that around 60,000 are employed reflecting the fact that companies 
engaged in manufacturing medical technologies sometimes do so as a secondary or tertiary activity. 
Hence people may be working full-time on medical applications but the principal activity of their employer 
is classified as something else.  In its latest report, the Government estimates that 52,000 people are 
employed in the sector in the UK (BIS/UKTI/DoH, 2009).  The overall trend in UK employment, based 
on a time-series derived from the Working Futures database, is presented in Figure 2.7.  The latest 
estimate for the UK would suggest that around 130,000 people are employed in the UK.
The Working Futures database suggests that around 92,000 people are employed in the bio-medical 
sector in the UK.  This may slightly under-estimate the number of people employed because of the 
difficulties associated with measuring employment in medical technologies (see above).  An upper-
estimate, based on the data cited by BIS (see above), suggests around 130,000 people employed in 
the sector in the UK.  If one were to take a mid-point between the two estimates this would indicate 
employment of around 110,000.
3 http://www.ukinvest.gov.uk/UKTI-publications/4046341/en-GB.html (accessed October 2009)
4 http://www.berr.gov.uk/whatwedo/sectors/biotech/pharmaceutical/page10219.html
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Figure 2.7 Employment Trends in the Bio-medical sector in the UK, 1971-2020
 
 
Source: Cambridge Econometrics Database; own calculations
 
Employment in the sector is divided between a limited number of large multinational corporations 
and a large number of small organisations.  In general, the larger employers have sought to manage 
risk and cost containment by outsourcing key activities often to smaller organisations.  In certain 
segments of the market, small employers are numerous because they represent spin-off companies 
seeking to develop new products.  This can also mean that the population of employers can be 
volatile with a large number of new entrants and exits each year (Critical I, 2006a and 2006b). In 
addition, until relatively recently when the economic downturn commenced, there was a high level of 
merger and acquisition activity, with key large players taking over small ones when they were near 
to bringing a product to market.
In sub-sectors such as medical technologies the structure of the market appears skewed towards 
medium sized companies (34 per cent of all employment in medical technologies was in companies 
with 50-249 employees), and 31 per cent with more than 250 employees (BERR, 2008).  Other data 
suggests that 47 per cent of companies in medical technologies have between 0 and 4 employees 
and 6 per cent more than 100 (BIS/UKTI/DoH, 2009). As previously mentioned, estimates of the 
size of medical technologies sector need to be treated with some caution because many companies 
significantly engaged in the sector are not necessarily classified as medical technology companies 
where their principal product relates to another good or service.  The LFS, because it asks people 
about the main activity of their employer which people will tend to answer with respect to the activities 
they are involved in, surmounts this problem to a degree.  Based on LFS data for England it is 
possible to look at the extent to which employment is accounted for by organizations of different 
sizes, and the regional distribution of employment.
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The size structure of the market varies by sub-sector and size (see Figure 2.8) with smaller workplaces 
accounting for a larger percentage of employment in the medical technologies sub-sector.  The size 
structure of the sector is important.  As will be highlighted later, commentators have mentioned 
that smaller firms often lack access to venture capital, and the practical know-how needed to bring 
a product to market, or navigate the procurement regulations which govern the health service. 
Moreover, from a training and skills development perspective, smaller employers often face a unique 
set of problems (Edwards, 2009; Hogarth et al., 2009; Bosworth, 2009).
In contrast to the medical technologies sector, in the pharmaceutical industry employment is 
concentrated in large companies.  The UK is the home of some of the largest pharmaceutical 
companies in the world such as Astra Zeneca and GlaxoSmithKline.  Though many of the large 
pharmaceutical companies are also involved in medical biotechnology, where firms are wholly 
engaged in this activity they tend to be small.  The medical biotechnology sub-sector is comprised 
mainly of SMEs with 99 per cent of companies having less than 249 employees (BIS / UKTI / DoH, 
2009).  Indeed, the evidence suggests that 42 per cent of companies have been 0 and 4 employees 
in this sub-sector, and only 4 per cent had more than 100 employees.  As noted above, the medical 
biotechnology sector is characterised by a large number of small enterprises, which have been in 
existence for only a few years which have the aim of capitalising upon an idea or innovation.
Figure 2.8 Percentage of Employment by Size of Workplace in England, 2009
(a) Pharmaceuticals
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(b) Medical technologies
 
Source: Labour Force Survey; own calculations
 
 
There is a significant concentration of employment in the East of England in relation to pharmaceuticals 
(38 per cent of all employment in England), followed by the South East (18 per cent) and North West 
(17 per cent) – see Figure 2.9.  In relation to medical biotechnology, the South East and East of 
England are the main areas for employment (BIS/UKTI/DoH, 2009). In medical technologies, the 
South East region accounts for around a third of all employment in England (32 per cent).  There 
does appear to be significant agglomerations of activity not just in England (especially so around 
Cambridge, the Thames Valley west of London, and the North West), but also across the US and 
Europe.  The evidence suggests that companies’ location decisions may be determined by the 
existing presence of similar types of company (Deloittes, 2009; Rinaldi, 2007).
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Figure 2.9 Percentage of Employment by Region, 2009
(a) Pharmaceuticals
  
(b) Medical technologies
  
Source: Labour Force Survey; own calculations
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2.6 Conclusion
The brief summary provided above indicates that the Bio-medical sector is important to the UK economy 
with respect to levels of output, employment, and R&D.  In the UK it is estimated to employ between 
92,000 and 130,000 people directly.  A mid-point estimate suggests employment of around 110,000. 
Its strategic importance, perhaps, lies in the likely development of new products and processes over 
the medium term – reflected in the relatively high levels of R&D expenditure – which have the capacity 
to generate a large volume of employment.  As the next chapter will indicate, there is a degree of 
uncertainty over where those jobs will be created, especially those related to manufacturing.
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3.1 Drivers of Change
The bio-medical market is undergoing a period of major change including:
• the shift from chemical to biological based pharmaceuticals;
• the greater use of biomaterials;
• a decrease in the ratio of new products coming to market relative to investments in R&D;
• a slowdown in product development due to the economic slowdown;
• pressures to reduce costs and lower prices especially for pharmaceuticals;
• increased use of outsourcing and networked solutions in production in an effort to increase efficiency;
• a shift in emphasis towards the invention of preventive therapies and treatments to aid well being;
• the potential to integrate technologies and drug treatments to reduce in-hospital care.
The general view is that the pharmaceutical and medical technologies sectors have suffered less 
than some other sectors during the current economic downturn, but have not been wholly immune to 
its effects on output and employment.  Indeed, the pharmaceuticals sector across the world appears 
to have been barely affected by previous recessions (Vfa, 2009).  But as the following discussion will 
demonstrate there are significant drivers of change in the sector which will have consequences for 
levels of employment and skills demand.
The principal drivers of employment change in the sector are:
• technology;
• innovation and R&D;
• health expenditure / public sector spending constraints;
• demographic change;
• regulation;
3 Factors Driving Change
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• sustainability;
• corporate strategic choice and globalisation.
How these are affecting the industry is explored in the remainder of this chapter.
3.2 Technology and Innovation
The study has identified a number of technological changes both in products and processes.  From 
a product perspective these can be largely categorised into those summarised in Table 3.1.
Specific and current examples of these changes and innovations have been mentioned by respondents 
in interviews or picked up in the literature and information searches.  Some of these that relate to 
change in the sector as a whole are commented on below and those with a specific link into the West 
Midlands are commented on in the case study section.
There is a long way to go, but there is increasing recognition of the benefits and advantages of using 
the human’s own systems (as in stem cell processes) or other “natural” substances and processes 
in a bacteriological or other biologically based system to produce compounds and structures rather 
than a chemically based manufacturing process.  In many instances there is a better chance of bio 
compatibility with the human body and reduced risk of adverse reaction or rejection - apart from the 
economics involved.
A much improved understanding of genetics is leading to a raft of new processes including the 
possibility of genetic modification to avoid predispositions to disease as well as the possibility of 
customised solutions to particular conditions.  There are major ethical considerations in this whole 
area of research and therapy development and these may well slow or change progress considerably 
but potentially such approaches could lead to a major shift in the way that we address diseases and 
their transmissions.  The convergence of biological, chemical, genetic, computational, medical and 
related healthcare sciences is leading to the growth of multi disciplinary groups including “life science” 
faculties in the HE sector including England.  This carries a number of implications at the strategic 
skills level in R&D in the public and private sectors and will flow over into senior management and 
personnel in the sector’s leading corporations and collaborating companies.  At a process level, 
there will be a range of regulatory and training issues but largely a requirement for adaptation.
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Table 3.1 Technology Drivers
Technology Pharmaceutical (P) or 
Medical Device (MD) 
Description
Bio-pharmaceuticals P The use of biological rather than chemical agents in drug 
treatments 
Personalised medicine (i.e. medicines 
which are designed to take into account 
the individual’s genetic code)
P Personalised medicine focused on using individuals’ 
genomic information and other personal traits to inform 
decisions about their health care 
Regenerative / predictive / preventative 
medicines
P Testing which can identify ailments which are likely to 
emerge, treatments to offset those ailments (e.g. via 
personalised medicines), or to regenerate decaying tissues  
Bioinformatics P The combination of information technology with 
biotechnologies, the capacity to store information in digital 
format, model or simulate biological processes  
Biological devices P / MD The medical technologies which are at the interface with the 
development of biological & pharmaceutical therapies 
Implantable devices / biomaterials MD Implants which are designed to remain in the body after a 
procedure (e.g. pacemakers, cochlear implants, etc.) 
External  devices MD Including surgical equipment, orthopaedic supports & 
therapy related devices 
Diagnostic devices MD The diagnosis of disease through a range of sensors to 
detect physical and functional abnormalities 
Informatics MD Increasing the use of wireless technology to provide data & 
its analysis, remotely, for clinicians 
Nanotechnology MD The miniaturisation of components and devices, especially for 
implants, invasive procedures & “lab on a chip” technologies 
Imaging MD Composite imaging from MRI, CT, ultrasound  and other 
techniques to show soft & hard tissues as well as brain 
responses to stimulation
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In looking at the drivers, there are both long and short-term demands made upon the sector.  Short-
term demands include the capacity to react quickly to issues such as swine flu which has been a 
huge learning opportunity for the whole healthcare sector from statistical prediction of pandemic 
evolution and spread in a highly mobile modern society to the time scales available to develop and 
produce politically acceptable and equitable supplies of pharmaceuticals, to the possibilities and 
effectiveness of infection controls – not to mention the health economics involved.  Each of these 
areas carry implications for the availability and volume of skills required and while the swine flu 
situation cannot be regarded as over yet, there is enough data to recognise how difficult it is, and 
will be, for any stable economic structure to ever cope with that degree of fluctuation in demands, 
expectations or delivery of skills.
There are also longer term demands such as the need to be more effective with a range of relatively 
common diseases, including treating long-standing problems related to increasingly difficult infections 
such as MRSA, C-Difficile, etc.  Treatment of long-standing problems or infections is giving rise to a 
number of practical innovations, such as using UV light to kill airborne pathogens such as these, push 
plate door surface materials, and door handles being coated to limit or prevent infection transfer and 
cross infection.  These solutions prompt the potential of a much better understanding of biological / 
material interfaces to assist with the limitation and prevention of spreading disease.
There are new imaging techniques including proton and heavy ion devices which will improve the ability 
to image nerves and soft tissues.  Such techniques are expensive at present but are expected to come 
down in cost as laser and other acceleration techniques improve.  Whilst the development of the machines 
themselves has tended to focus on big companies in the USA and Germany, there is significant research 
activity in England on image analysis techniques and processing software.   New ultrasonic developments 
are also providing better imaging techniques for nerves and the surrounding tissues.
Better imaging and understanding of soft tissues and neural pathways is also going hand in hand with 
new approaches to regenerative techniques and physio therapies.  For the first time it is becoming 
more practical to provide feedback of results from nerve regeneration concepts.  Apart from traumatic 
conditions, it is equally becoming easier to map the physical manifestation of mental stress and 
depressive disorders which affect significant proportions of the population.
It is making increasing sense for psychoanalysts and psychiatrists to work much more closely with 
medical engineers in such fields but there is an expectation that there will be a large gap opening up 
between the demand for such skills and their availability.  This links closely with English University & 
NHS project groups working with these imaging techniques and also with NHS PCT based pathfinder 
programmes to increase the number of competent mental health staff to work alongside an increase 
in access to Computer Based Cognitive Therapies.
Regenerative medicine and healthcare techniques are on the brink of major change, closely linked 
to stem cell and genetic research.  There is every expectation that within the next few years it will be 
possible for women to re-grow their own breast after surgical removal of cancerous tissue.
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Whilst such regenerative technologies and genetic techniques are opening up new horizons for 
healthcare, they are also opening up minefields of ethical considerations which may well slow their 
adoption.  Insurance companies, for example, would dearly like to know the genetic disposition and 
susceptibility of their clients to differentiate insurance risks and to limit access to insurance by poor 
prospect clients.
Telemedicine and healthcare support in a domestic or care home environment is becoming increasingly 
prominent with more and more sensor and monitoring devices coming on to the market.  The explosion 
of such devices also links closely to the use of less invasive technologies as well as the use of 
technologies and techniques that are more robust in untrained hands – promoting private consumer 
purchase as much as purchase by professional practices.  Devices include stand alone ECG, blood 
pressure and monitors of other vital signs but they also include the development of intelligent clothing 
items for longer term wear.  In less than 18 months in the UK, for example, there has been the spread 
and availability of “DIY” defibrillators into many public buildings and other strategic locations.
The concept for many of these sensory devices is that they will link into the Primary Care structure 
in England with the General Practitioner as a key focal point for monitoring what is happening as 
far as the patient and their healthcare are concerned.  This presents major skills issues for PCT 
structures which are not geared up to provide Continuing Professional Development in relation to 
such technologies and there is already a shortfall of technicians to provide support.
The trend to miniaturisation continues, both from the point of view of less invasive procedures and 
from the point of view of smaller, lighter and more portable devices.
By the end of this year there is an expectation that cancer will have replaced cardiovascular disease as 
the main disease related cause of death throughout the world.  During 2010 it is estimated that 12 million 
new instances of neoplastic disease will occur throughout the world and that 7 million people will die from 
a malignant tumour according to the World Health Organisation Institute for Cancer Research.
The technological breakthroughs which are being made – as evidenced in the next chapter on patent 
activity – are taking place to differing degrees.  For example, while blue-skies research is making 
advances in stem-cell research this is yet to materialise in major products being brought to market, while 
in the medical technologies sector more incremental changes are materialising which has resulted 
in new applications and products being developed.  To some extent, the technological challenge 
facing the pharmaceutical sector is a formidable one.  Many existing, high earning medications are 
nearing the end of the patents which will allow in generic manufacturers; at the same time, though 
pharmaceutical R&D expenditure is increasing, proportionately fewer new products are coming to 
market (ABPI, 2008).  In other words, new products require higher expenditure on R&D. 
It is not just physical health which can be assisted through the use of medical technologies.  Treating 
psychological distress can also be assisted through the development of suitable suites of software to 
deliver self-help programmes which may have the potential to avoid people requiring drug treatments. 
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Serious Games techniques are particularly appropriate in the case of Cognitive Behaviour Therapies 
(CBT) and are likely to play a much more important role in a range of depression and other mental 
health problems in the future. Hence there is a direct linkage to the software services sector.
3.2 Health Expenditure Public Sector Spending Constraints
Technological advances are taking place against a background of a need to reduce health care costs 
in many countries – either because of the insurance premiums required to cover health care costs, 
or because of pressures in general on public expenditure in many countries in the West and a need 
to curb the infinite demands which are being placed on health care systems due to demographic 
change and increased consumer awareness of the availability of treatments.  While it is apparent 
that the UK spends relatively less of its GDP on health care, like many other countries it is dependent 
upon public expenditure to meet much of its health care costs (see Figures 3.1 and 3.2). Hence, a 
further driver of demand is public expenditure on health care.
Figure 3.1 Share of GDP on Health Care
 
Source: OECD
Figure 3.2 Share of Total Health Care Accounted for by Public Expenditure
 
 
 
Source: OECD
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One potential outcome of the rising pressures on current healthcare systems and the increasing 
impossibility of their economics could be an increased recognition of the importance of sensing 
and diagnosis of illness at a much earlier stage and of focusing funding systems and healthcare 
structures on a much higher proportion of preventive measures and cures.
Despite better knowledge and an increasing array of therapies it is still expected that 50 per cent 
of people contracting cancer will die of the disease.  New medications being used in oncology can 
be up to 300 per cent more expensive than traditional approaches yet are only 20 per cent effective 
– posing a major problem for health economists.  There are already numerous heartrending cases 
reported in the press where the health service cannot afford to make treatments freely available to 
everybody and where selective criteria have to be applied.
The problems of health economics are also manifesting themselves in other ways for the 
pharmaceutical industry.  Pharmaceutical companies are structured financially to recover the 
enormous and increasing research and development costs of new drug discovery on the back of 
drug sales.  If the drug is a therapy which is likely to be applied multiple times by a patient in the 
course of their lifetime and if a high percentage of the population is likely to be or become a patient 
then the drug rapidly becomes a low cost Over-The-Counter (OTC) product.  If the drug is a cure 
only ever used once by a small percentage of the population then it is an extremely, and increasingly, 
difficult equation to balance - whether the drug is publicly or privately funded.
3.3 Demographic Change and Consumer Demand
Part of the challenge facing the industry is the development of medicines and devices which will help 
manage a number of health care challenges.  There is an on-going demand to develop therapies 
which will alleviate, manage, or cure a number of life limiting or fatal “dread” diseases (e.g. cancer) 
and chronic conditions (e.g. diabetes) all of which come with a high cost of healthcare.  This demand 
has been exacerbated by an increase in life expectancy whereby the number of years the health 
service needs to treat a person with a chronic disease has increased, and a consequence of increased 
longevity is that the probability of someone developing a dread illness and / or chronic condition has 
also increased.
The increase in longevity also means that implants, not least orthopaedic ones, are now expected 
to be in place for a longer period than the life of the device or its fixation, leading to the need for a 
second, and in some cases a third, operation and replacement device.
Moreover, people are more aware of the therapies available – hence people are challenging the 
decisions where their health care systems are unwilling to fund treatments – and while they may not 
be able to influence their clinicians in the public health care system, there is the option to purchase 
these therapies privately.  While this has placed enormous pressures on health care systems around 
the world it has, at the same time, created a potentially lucrative market for medicines and medical 
technologies which will relieve pressures on the health care system.
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In England and elsewhere, an increasing range of healthcare therapies and devices being sold 
over the counter of pharmacists and drug stores or through specialist technology outlets has been 
observed.  Increased consumer awareness of their own health, coupled with much higher levels of 
discretionary spend available to many people, is leading to a growth in the OTC sale of personal 
health monitoring devices which used to be the prerogative of the clinician including stethoscopes, 
blood pressure instruments and heart rate monitoring devices.
Similarly, in relation to medical technologies, there is increasing attention being focused on developing 
devices which are either stand alone delivering direct benefits to the patient/user or allow for remote 
monitoring, diagnosis, and treatment through independent or private services using the improved 
mobile phone, WiFi or various information technology and communication networks.
As far as being a market opportunity is concerned, this has been succinctly expressed:
 “In the United States which accounts for approximately 43 per cent of total industry sales, medical device 
companies view the hips and hearts of the 78 million-strong, baby boomer population with an accountants 
green eyeshade.  Globally the trends are equally compelling.  In the developed nations, the population of 
older than 60 years will climb to 33 per cent in 2050 from 19 per cent in 1999” (Hodson et al., 2008. p.1).
3.4 Regulation
It is not just in relation to permitting research to take place that regulation has an effect, there is also the 
process by which medicines, therapies, and devices are approved for use.  There are stringent rules 
across the Western world in this regard.  In many respects, given the global nature of the system, it is 
not just about obtaining approval for a product in the UK and then gaining access to the NHS, but also 
achieving the same in other health care markets.  This can be a particular problem for SMEs.
Depending upon the relative regulatory burden in the UK compared to other countries, this can speed 
up bringing products to market.  This is not just related to the speed with which product licences are 
granted but also the ease of access to the health service procurement system.  As will be discussed 
later, one of the principal skill needs of medical technology producers is the capability to develop 
effective relationships with the NHS. Regulation, however, ought to be viewed in a European and 
international context too since companies are often looking to market their products globally.
3.5 Sustainability
With reference to the sustainability agenda, the health service is one of the largest guilty parties when it 
comes to once only use rather than re-use of devices and instrumentation etc. let alone synthetic drapes, 
textiles, paper and many other materials.  Sterilisation technologies and methodologies are coming 
under the focus again to become a more sustainable sector.  This relates very much to understanding 
the bio burden and how you can avoid creating waste in the first instance and, if unavoidable, how you 
make it safe (e.g. sterile) in the most energy and waste limiting way possible.
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There are also examples of companies in England which are currently operating a supply chain that 
is extended across the world to pick up low labour cost components and who are now looking at the 
economics more carefully.  The low labour costs are coming under pressure in many cases, volume 
commitment to contracts mitigates against flexibility of design change and customisation demands 
makes that even worse.  The ability to innovate and at the same time maintain quality and reliability 
standards is also more difficult at a distance and in different cultures.  Just as there is now recognition 
of climate change and carbon costs to be accounted for in regard to food miles, so there is also an 
increasing awareness of the likelihood of component and material miles.  In some cases, companies 
are taking a strategic decision to bring manufacture, or elements of it, nearer to the product assembly 
plant, largely for sustainability reasons.
3.6 Corporate Strategic Choice and Globalisation
How bio-medical companies will respond to changes in the market is a moot point.  It is evident 
that the market for health care goods is an international one in two respects: (i) many of the leading 
companies are multi-nationals; and (ii) there are significant trade flows in bio-medical goods both in 
intermediate and final products.  Hence, companies have a degree of strategic choice in where they 
locate their activities.  To date there is evidence of the sector outsourcing many of its activities across 
the world.  Although the sector is not wholly geographically mobile given the costs of establishing, 
for instance, pharmaceutical plants, companies nevertheless have some choice as to where they 
undertake their R&D, product development, and manufacturing.  Companies clearly have the option 
of transferring their mass production activities to counties with lower labour costs (Cogent, 2009). 
At the same time, the introduction of bio-pharmaceuticals, personalised medicine, new medical 
technologies will stimulate growth in niche producers many of which are SMEs.
As already noted, the sector as a whole is comprised of a few large multi-nationals and a multitude 
of SMEs.  In the UK, there is the potential for more employment to become concentrated in the SME 
segment of the market which raises demand for skill sets appropriate to this group of companies. 
SMEs capability to fully develop their innovations can be limited with evidence pointing to difficulties 
in raising venture capital to successfully bring products to market (Deloittes, 2008).  Moreover, SMEs 
also lack the know-how to navigate their way around the procurement systems in national health care 
systems.  At the same time, part of the strategic choice the industry’s leading players have adopted 
is to allow smaller companies to develop products and processes and then acquire the companies 
when their innovations have proven market potential.
There are some advantages for SMEs in the healthcare sector however, including the relatively low 
volumes needed for many of the devices and innovations.  Generally this means that if there is a 
defined healthcare need, albeit in low numbers, that the cost – price relationship is not as critical as it 
may be in other sectors and the lower volumes are also less likely to attract big company, big market 
competitors.  It is factors such as this that have encouraged the growth that has taken place in areas 
such as the West Midlands where much of the activity has come about through diversification from 
other sectors under severe cost – price pressures (Hogarth et al., 2005).
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Spin-off companies are an important means of generating agglomerations or clusters of, typically, 
high value goods and services.  Some stakeholders recognise that spin-off companies often lack 
the investment and management capability to successfully bring their products to market.  This is 
especially so in relation to dealing with the various regulatory bodies which grant product licences and 
also accessing the health service procurement system. The larger companies, in contrast, possess the 
wherewithal to engage with national procurement systems in abundance.
The above points to the importance of networks between companies.  Whilst these can be developed on 
a national or international basis there is a tendency for companies to cluster together in selected locations. 
Hence in countries such as the USA, Germany and the UK it is apparent that agglomerations of activity have 
developed.   In the USA, there are clusters of activity in Boston, Illinois, New Jersey, and northern California; 
in Germany around Baden Württemberg and Bavaria, and in the UK around Cambridge, a corridor between 
Oxford and West London taking in the Thames Valley, the North West, and around Edinburgh.  Part of the 
agglomeration process, certainly in relation to the development of new products and processes, appears to 
be driven by the linkages with the R&D sector especially in the higher education sector.
For the time being, especially so in pharmaceuticals, the UK as a whole is well placed to capture the 
R&D / product innovation segment of the market given its existing strengths.  The establishment of 
industry links with the HE / R&D sector – which is driving both innovation and regional specialisation 
– has played an important role here, as has the regulatory environment in which research has taken 
place.  The UK, in contrast to the USA, has had a more supportive attitude to public funding of stem 
cell research whereas under the administration of President Bush Jnr., there was an eighty-year ban on 
federally funded research (FT, 2009).
3.7 Conclusion
As Map 2.1 above revealed there are many centres around the world which have created a critical 
mass of activity in the life sciences.  To date, the pharmaceutical industry in the UK, rather more 
than the medical technologies sector, has been successful in maintaining a critical mass of activity. 
There is evidence that countries such as Germany (Baden Württemberg and Bavaria) and the USA 
have been more successful in capturing the market for big-ticket items, such as imaging equipment, 
in the medical technologies market.  Part of the UK’s relative strength relates to its existing strong 
base, especially in pharmaceuticals, and the strength of the higher education system.  Meeting the 
challenge of globalisation relates to:
• supporting spin-off ventures by ensuring they have the capital and skills to bring innovations to market;
• establishing incentives for industry – HEI collaboration (c.f. the Lambert Review5);
• maintaining a strong skills base, especially so amongst highly qualified scientists and engineers.
5 The Lambert Review of Business Industry Collaboration (Lambert, 2003) drew attention to the importance of HE- industry collaboration for both regional 
and national economic growth and competitiveness.  It also drew attention to the competing demands made upon HEIs.
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It was noted that many of the major companies operating in the sector are large multinationals which 
have a degree of strategic choice as to where they locate their R&D and manufacturing activities. 
Hence the importance of establishing a strong intellectual base for the development of the sector 
since this is likely to retain activities in a given place.  Research reveals that while many top scientists 
regard themselves as highly geographically mobile, few have any desire to move (Feldman, 2001). 
Hence the UK’s existing strong intellectual base provides it with a key strategic advantage.
Despite the relatively strong position from which the UK starts there are a number of challenges which 
need to be met if the sector is to continue to be a major source of value-added and employment. 
These are summarised in Table 3.2 below alongside the implications for employment.  Technological 
change and innovation in the bio-medical sector – and especially in medical biotechnologies – 
suggests that its economic prospects are good.  Perhaps of all the manufacturing sectors it is the 
only where a substantial decline in employment is not projected in the period to 2020.  Employment 
prospects are, however, a little uncertain.  While there is no evidence that sector will experience any 
major fall in employment in the period to 2020 it is apparent that over the longer-term that the growth 
in world markets will see production and, perhaps, R&D activity increasingly located in emerging 
markets.  So long as output levels continue to grow at their current rate this may have a relatively 
modest impact on employment levels in the UK.  Moreover, the relative strength of the UK’s bio-
medical R&D sector is such that its pre-eminence will be maintained.  Strong output growth is, it 
must be said, dependent to some extent upon major scientific breakthroughs being translated into 
products, and those products being cost-effective.  While there is every reason to believe that this 
will increasingly occur, it cannot be taken for granted.
Related to the globalisation issue, though it is outside the scope of this report, is the capacity of the 
country to capture the supply chain for the provision of intermediate products and services used in 
the production of bio-medical goods.  This is likely to be a relatively large market though much of it 
will lie outside of the bio-medical industry as classified in this report.
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Table 3.2 Drivers of Demand in the Bio-medical Sector and their
Source: IER
Driver of Change Description Employment Implications 
Technological Change, 
Innovation and R&D
On-going research activity 
 
 
 
Major breakthroughs in new therapeutics
Strong demand for high skilled labour in the R&D 
sector, especially professional scientists and 
engineers 
 
Employment increases in relation to production of 
new products.  If niche production required this may 
be retained in England 
Health Expenditure The Exchequer in many EU countries is 
meeting majority of health care expenditure
The need for countries in the West to constrain real 
levels of public expenditure will boost the demand 
for cost-saving therapies (see above), but may 
inhibit the diffusion of more costly treatments 
Demographic Change Large market increase resulting from 
increased levels of life expectancy
A demand for products which reduce the costs 
imposed on national health care system resulting 
from people living longer – especially those who 
have chronic medical conditions.  This has the 
potential to boost employment levels. 
Regulation Permissive attitude towards conducting 
stem cell research has benefited UK R&D 
 
 
Regulation of products 
 
 
Increases employment in R&D – and draws in 
scientists from around the world.  Has the potential to 
increase production jobs if new products materialise. 
 
Can inhibit employment growth where firms (SMEs) 
struggle with the process of meeting national safety 
requirements and selling to national health care 
systems.   
Sustainability Need to reduce waste levels/improved 
waste disposal 
 
Energy conservation
Design of products which limit waste 
 
 
Use of new materials/bio materials 
Strategic Choice Outsourcing of critical mass of activity to 
other countries 
 
 
 
 
 
Outsourcing product development to SMEs 
 
 
 
 
 
 
 
Opening of new markets in developing 
countries
Threat of mass production being moved to countries 
with lower cost production. Potentially leaves 
England with R&D and product development, 
perhaps linked to production of small scale 
output. But large scale employment decline is not 
realistically on the horizon to 2020. 
 
There has been growth of the SME sector, 
especially in biotechnology. But as small firms 
they face a number of potential barriers relating 
to obtaining capital, negotiating the health system 
which may affect employment levels. Employment 
levels depend upon the extent to which UK 
manufacturers can capture this market. 
 
Whilst there is the potential for export activities, 
globalisation is likely to result in production taking 
place in new emerging markets, coupled to prices 
being driven down. R&D employment is still likely to 
be in the UK, but some may increasingly be located 
in the markets being served.
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4.1 Aims and Scope
The present section explores emerging technological trends relevant to the bio-medical sector.  The 
future prospects and skill requirements of any given sector depend crucially on the underlying rate 
and nature of technological change (e.g. relating to the invention of new products and processes), 
as well as the speed of diffusion (use in production) of these new technologies across the relevant 
parts of the economy.6 Information about emerging technological changes can rarely be directly 
translated into precise implications for current and future skills needs, but knowledge of the changing 
technological landscape can be an important weapon in the strategic planner’s armoury.
Systematic work on monitoring the rate and direction of technological change and investigating its 
effects on growth and performance began to emerge in earnest as long ago as the late 1940s and early 
1950s (e.g. Solow, 1956, 1957, and Jorgensen and Griliches, 1967), with more recent work associated 
with the emergence of the “new growth theories” (e.g. Romer, 1986, 1990, and Lucas, 1988, as well 
as a review by Solow (1991).  This section draws upon several aspects of the empirical strand of this 
area of research, including R&D statistics (e.g. Bosworth, et al. 1993) and, more particularly, patent 
data (e.g. the series of articles about the uses of US patent statistics by Schmookler, leading up to 
Schmookler, 1966); for a review of the early literature see Bosworth, 1987).
Enormous strides have been made in the empirical investigation of technological change with the 
emergence of large scale electronic R&D, patent and scientific publication data bases, and there is the 
scope for significant further research, beyond that undertaken as part of the present study, that would aid 
policy design in this area (see Appendix 2 for a brief discussion of the use and limitations of patent statistics 
for the present purposes).  The present work focuses primarily on the patent information, where much 
more detail is available about the areas of technology in which advances are accelerating or declining.
This section continues with a discussion of many of the conceptual issues associated with understanding 
the central role of technological change in influencing future skill needs (Section 4.2).  While the question 
of high level skills is discussed, including those associated with the invention and innovation processes, 
consideration is also given to broader issues of skill demands at the sectoral and national levels, caused 
by the nature of technological change, and the rates of innovation and diffusion of new technologies. 
Section 4.3 provides a brief discussion of the trends in health related R&D in the UK and, for comparative 
purposes in the USA.  Section 4.4 goes on to consider patenting activity by area of health technology, 
attempting to identify areas of rapid technological advance, particularly those in which Europe remains an 
important player, and areas where technological opportunities appear to be diminishing and/or the USA 
and Japan appear to be developing a major technological advantage.  Finally, Section 4.5 provides the 
main conclusions of the present section.  In doing so, it sets out some of the main findings about areas 
of continuing technological opportunity, but also about the degree of competition in the production of 
new technologies globally.  In addition, the conclusions outline some of the ongoing research designed 
to bring the study more in line with sectoral interests, such as the investigation of technological activity 
4 Technological Progress in the  
 Bio-medical Sector
6 This should not be taken as an indication either that technology is the only driver or that change in the sector is simply driven by technological 
opportunities.  The speed and direction of technological change is itself a function of many of the other opportunities and challenges facing the sector; some 
of these influences are set out in EFILWC (2007).
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according to six alternative “technology platforms”, which would be recognised by players in the sector, 
as well as by four different areas of application within the health sector (see Appendix 3).
4.2 Conceptual framework
4.2.1 Conceptual issues
Projecting future skill needs is not possible without an understanding of technical and technological 
changes:
• technical changes occur where the technology set is given (e.g. the product and process 
technologies), but nevertheless there is a substitution of one input for another (e.g. from less to 
more highly qualified labour as the latter become relatively more efficient in production); and,
• technological changes are associated with changes in the technology sets themselves (e.g. new 
products are produced or new processes emerge).
Technical changes are often driven by movements in relative factor prices.  For example, as skilled 
labour become more expensive relative to less skilled labour, there is an incentive to economise on 
the more skilled workers and utilise a higher proportion of the less skilled workers.
Technological change can be:
• skill-neutral, for example, where a given mix of more and less highly qualified labour become 
increasingly productive – proportionately less of both are needed – because of improvements 
in technology;
• skill-biased, for example where improvements in technology save more of one type of labour 
(e.g. relatively more unskilled labour is saved per unit of output than skilled labour, causing  
a relative shift towards the demand for skilled labour at current relative factor prices).
The effects of technological change on skill levels are not fixed over the life of the technology (as 
the discussion of technical changes suggests).  The initial stages of technological change are often 
relatively skill intensive, but, as the technology matures and competition in the area of techology 
increases, there are greater incentives to seek ways of economising on the more expensive, skilled 
labour and utilise less skilled individuals.  These sources of competitive improvements often lead to 
the movement of technologies away from the initial innovating country to parts of the globe where, at 
some point in the changing skill needs of the technology as it matures, broadly the same skill levels 
can be obtained at lower factor prices.
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Technological change may have both quantity and quality dimensions; technological change 
may increase:
• the number of units of output that can be produced with any given volume of inputs (e.g. person 
hours of skilled and unskilled labour);
• the quality of the existing units of output that are produced with any given volume of inputs.
Of course, the quality of inputs may also change, for example, as highly qualified labour assimilates 
new knowledge which improves the productivity of this type of labour in the production process (see 
Bosworth, 2005, pp. 69-102).
The present section focuses on technological changes, which will, in principle, if adopted, drive 
future skills needs as they impact on products and processes used in the supply of health care.  This 
is carried out at a broad level of technological activities (see Section 4.4 for further details), as it is 
at this level that can probably best inform government policy about skills trends at the leading edge. 
However, future work needs to also consider the resulting future technological changes that might 
accompany such trends.
4.2.2 Technological Forecasting
Technological foresight
Technology foresight is widely recognised as a source of strategic information for policy making.  It 
can be defined as:
 “... the systematic attempt to look into the longer-term future of science, technology, the economy 
and society, with the aim of identifying the areas of strategic research and the emerging of generic 
technologies likely to yield the greatest economic and social benefits” (Martin, 1995, 140).
Foresight has been associated with “picking winners”, but, in more recent years, it has been 
recognised as having a more nuanced set of roles, for example,
• “Foresight is no longer undertaken with the claim to forecast or predict a certain future situation 
but recognises the possibility of alternative futures and also tries to shape or create certain paths 
of development;
• the foresight process with its stimulation of communication and future orientation among the 
actors of the innovation system is regarded at least as important as the outcomes in terms of 
identified areas of strategic research and emerging generic technologies;
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• accordingly, the function of mobilising and ‘wiring up’ national innovation systems adds to the 
function of informing science and technology policy-making, e. g. for purposes of priority setting”. 
(Aichholzer, 2001, p. 3)
According to Eerola and Jørgensen (2002, p. I and p. 12), Nordic technology foresight (TF) is defined as:
 “… systematic, future-oriented interaction processes contributing to shared visions concerning 
long-term technological developments. In the TF exercises, technological developments are 
examined in their real-world, economic and societal context, with attention to a wide pool of 
knowledge and the viewpoints of various interest groups. The processes can be broad-scope 
or more focused. The purpose is to facilitate communication between the interest groups and 
to increase decision-makers’ and key actors’ knowledge base, so that desirable technological 
developments can be supported with relevant Nordic strategies, decisions and actions.  Both 
analyses and interaction are important in this respect”. [itals added]
Demand-pull
As will be discussed further below, however, a demand-pull focus is also needed to balance out the 
tendency for technology foresight exercises to be inherently technology-push in nature when examining 
these issues (ibid. p. 6).  The problem arises from the tendency to rely too heavily on experts from the 
“supply-side”.  The Austrian Delphi study recognises this area of potential bias, acknowledging that it “… 
ought to give an at least equal weight to demand”, however, “[m]ethods to forecast long-term demand 
for high-tech goods … are still lacking” (Aichholzer, 2001,. p. 9).7 Examples of attempts to consider the 
demand-side for key French technologies can be found in Durand (2003).
One key area where, in some sense, demand is relatively easy to establish is that of health needs.  It 
is possible, for example, to identify illnesses and diseases for which new technologies will ameliorate 
human suffering and extend human life.  The problem here is that pricing is a major ethical issue in 
the control of “demand” and the health sector is forced to operate systems which translate “demand” 
(or “want”) into “need”, by means of medical judgement (an across the board form of triage).  Here 
judgements may be informed by growing statistical evidence of quality adjusted life years (QALY).
In the UK, the largest source of demand for medical technologies is the NHS, which intermediates 
between the health demands of individuals and “health supply”.  In the context of the present study, 
the Department of Health has recognised the failure to fully realise the potential benefits of new 
medical technologies (House of Commons Health Committee, 2005).  Several reasons have been 
put forward, for example, that:
7 The Austrian study breaks down the demand side into relevant fields, which distinguish between technological focus (e.g. medical technology and support 
for elderly people) and societal/cultural focus (e.g. ageing and life cycle).  It also notes the role of “political factors” where society’s (voters’) views (e.g. 
about changes to the health insurance system) may intervene in selecting areas for future development..
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 “The NHS comprises a federation of 700 Trusts; inconsistent policies and practices in relation 
to the development of new technology, its application and purchasing policies create difficulties 
for suppliers and result in variations in the availability of technologies to patients. The use of 
different and incompatible makes of equipment leads to many problems, including the need for 
training in the use of each piece of equipment. The result is a drain on resources and the potential 
for mistakes. The inability to move money between Trusts’ budgets can also result in a lack of 
integration.”  (HCHC, 2005, p. 3)
There is a tendency to think of these problems occurring within medical institutions (e.g. the surgery 
or hospital), but they are a wider issue:
 “There are limitations to the use of new technologies. They can be expensive, especially if not 
implemented correctly. Installing new technologies outside the clinical environment, for example 
in patients’ homes8, can create problems: patients can find it difficult to use the technology and the 
reduced human contact with practitioners might also be reflected in reduced contact with carers 
and kin; alternatively, it might increase the burden of responsibility on carers. However, handled 
properly these limitations should not be a bar to the wider use of the technologies.”  (ibid. p. 3)
4.2.3 Which Technologies?  Radical technologies, incremental innovations and the broader 
 aspects of technological and technical change
Research, health supply and outputs for use in the healthcare sector
When discussing medical technology, biotechnology and life sciences, there is a tendency to focus 
on radical developments – new technology platforms that will change the face of medicine (often 
referred to in economics as “general pupose technologies”, GPTs).  Undoubtedly such technologies 
are important, especially from a health perspective, and one would expect them to be adopted within 
the health service in the UK.  However, this is a different issue to the following:
• there may be other more incremental technological improvements that, while generating modest 
improvements to individual patients, neverthless can be of enormous benefit when considered 
across the health sector as a whole;
• the adoption new technologies by the health service is a quite distinct issue from the question 
of what new products, based on new and existing technologies, should be produced within the 
national economy.9 
8 This might also apply to residential and care homes, etc.
9 In a way, this is an issue that was wrestled with in the development of the theory of “comparative advantage”.  The fact is that different factor endowments 
(and different degrees of technological capability in different areas) mean that there are economic gains from different countries concentrating their efforts in 
areas or production where they have a relative (comparative) advantage. 
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Thus, there appear to be a number of issues here, although, in part, they are likely to be inter-related:
• what new technologies should the country be developing through research, medical testing and 
assessment, etc.;
• what new medical, biotechnology and life science technologies should the country be adopting for 
use in its health services;
• what new products and services to be used in the delivery of health services (not necessarily just 
for use domestically) should the country be producing?
The skills implications of each of these three questions are, to some extent, distinct:
• the development of new technologies might be carried out primarily through the science base, 
maintaining and developing high levels skills within universities, university hospitals, private R&D 
laboratories, etc.;
• the adoption of new medical, biotechnology and life science technologies is primarily the remit of 
the health sector, with implications for skills to ensure successful introduction of the technologies, 
but also implications for the skills (and skills mix) of staff who will operate the technologies to 
deliver new health improvements;
• the domestic production of products and services to be used (primarily) by the health sector 
(domestically and internationally) has implications for the skills of the relevant manufacturing and 
service sectors (largely outside of the health supply sector), which are the remit of the relevant 
SSCs (e.g. Cogent10, Semta11, etc.), although the input-output matrix linking business supply and 
demand will pull in a potentially much wider range of sectors.
Technological opportunity, mining and exhaustion
Bearing in mind their limitations, patent statistics can be used to identify areas of technological activity 
and the trends in such activity over time.  There is a rich literature setting out the uses, limitations 
and results of patent mapping activities (see particularly publications in Research Policy, e.g. Meyer, 
2000, Meyer, et al. 2004, and Engelsman and van Raan, 1994).  Patent statistics have been used to 
examine technological activity and the impact of such activity at most levels of disaggregation from 
the firm-, to the sector- and to national levels (e.g.  Griliches, 1995, through to, e.g. DIST, 1996 and 
DTI, 2001 – many of which have been annual publications of activity and performance).
10 Chemical and Pharmaceutical, Oil, Gas, Nuclear, Petroleum and Polymers (www.sscalliance.org/SSCs/LinkstoSSCs.aspx).
11 Science, Engineering and Manufacturing Technologies (www.sscalliance.org/SSCs/LinkstoSSCs.aspx).
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Figure 4.1 provides an example at a very detailed level, reporting the results of patenting activity through 
the USPTO, in the area of cephalosporins.  The annual year on year activity rises to a peak in the mid-
1970s, after which it falls as the area of technology becomes “exhausted” or some other more productive 
area of technology takes over.  The cumulative patent activity curve shows the broadly “sigmoidal” 
shape which tends to typify particular areas of technology.  Thus, again with some caution, the relative 
levels and shapes of such curves (both annual and cumulative) can be used in qualitatively assessing 
both the historical trends in activity and the future potential of particular areas of technology. 
Figure 4.1: Growth and decline of USPTO patenting activity in cephalosporins
 
 
Source: own data, constructed from interrogation of the USPTO patent database.
 
Taking an area of technology (e.g. luminosity), rather than a specific technology itself (e.g. mercury 
lamps) (see Wills, et al. 1972, pp. 106-109), there is often a cumulation of successive “sigmodial” 
curves that supersede each other.  Thus, the growth behaviour of a field of technology is often the sum-
total of many technological strands of advancement, each which generally follows its own “logistics-
type life story” (Shvartz, et al. 1981).  One approach to modelling the field of technology rather 
than individual technology strands is to fit a logistic envelope curve (e.g. tangential to the individual 
technology curves) (ibid.).  While evidence for such envelopes is not as prolific as for individual 
strands of technology, it seems very likely that these too are generally sigmoidal in shape.12 
12 In this case, the upper limit of the envelope function is often determined by some physical law (such as the speed of light).
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Technological change, diffusion and the “optimal mix of skills”
There is a tendency for political commentators to believe that producers should be using the most 
advanced technologies and, if they do not, then there is some “technology gap” that should be 
made up.  The technological diffusion literature indicates that this is clearly not the case.  Diffusion 
takes time and a variety of economic (and other) factors influence the pattern of diffusion, making it 
more profitable for some enterprises to be early adopters and some enterprises to be later adopters 
(Karshenas and Stoneman, 1993).  Of course, this does not mean to say that the influences on the 
rate of adoption are given and immutable, they themselves might be the subject of policy changes 
aimed at increasing social welfare (e.g. in the equality of provision across patients – see below).
Diffusion of any new technology is invariably “sigmoidal” in shape over time13.  A variety of functional 
forms have been used to represent the cumulative adoption of technologies over time, such as the 
logistic curve, which has long been recognised as characteristic of a great number of phenomena, 
including technological development (Ayers, 1969; Linstone and Sahal, 1976; Martino 1973).  As a 
new technology gradually takes over from an older technology (or a group of older technologies), 
new and old technologies coexist and do so, sometimes, for very extensive, periods of time.  Insofar 
as these new and old technologies require different skills to operate or produce them, this allows a 
sector to work with a mix of skill and qualification levels.
This may be essential from a labour market policy perspective, as a concentration of demand amongst 
the highly skilled and qualified would leave those supplying lower level skills without employment.  It might 
also result in an excess demand for those with high level skills, with associated higher wage rates for these 
groups, which reduce the profitability of the newest technologies and, thereby, their rate of diffusion.
On the other hand, in the health service it may create ethical, social and political problems, insofar as new 
technologies are being introduced in some parts of the service (with associated health benefits), but not 
in others (where individuals with the same health needs are being treated with the old technology).  This 
leads to political pressures, such as those associated with the so-called, “postcode lottery”.
Whatever the resulting problems, it is almost certainly the case that rates of diffusion are endogenously 
determined by factors such as skills availability (this has been apparent for many years, see, for 
example, Solo, 1966; Amsden, 1989), it also points to the fact that diffusion processes can be 
influenced by government and regional policy makers:14 
• this might be through incentives to produce new technologies or adopt new technologies, which 
would utilise higher educated and skilled individuals;
• equally, it may be through changing the supply of skills and qualifications of different types, of 
different levels and in different localities.
13 In some cases, such as technological failures, only part of the “s-shaped” diffusion curve may be observed.
14 In a sense, it is the entire national innovation system that is relevant, in other words, the entire network of institutions in the public and private sectors that 
interact to “… initiate, import, modify and diffuse new technologies” (Edquist, 1997).
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Radical and incremental technologies, and technology life-cycles – implications for a more 
holistic skills approach
Radical new technology platforms may be the major engines of future growth and development. 
However, their are at least three major considerations in governing their adoption and use:
• it does not always pay to be the (first15) innovator, later adoption is sometimes the more economic 
and socially optimal route (see the discussion of optimal diffusion and skills below) – likewise, it 
does not always pay to introduce the most radical advances, which may not be best suited to the 
economic, social or cultural needs of the population;16 
• incremental advances (see above) may be the only improvements available in some areas (in 
others they may complement more radical advances), but their impact across the health sector 
(and its customers and suppliers) as a whole may be significant, and the more so when their 
cumulative impact over time is taken into account;
• the contribution of technologies (new and old) should be viewed in the context of their life cycle and, 
what many commentators omit, in the context of the need to manage their life cycle (Bosworth, 
2005, pp. 352-359).
While there can be intense “consumer pressure” for the adoption of the most advanced health technologies 
in relatively wealthy nations, such as the UK, it is not clear that this is always the socially optimal route. 
For example, the benefits of the most advanced technologies (which are often very expense in their early 
stages) may only be afforded at the cost of a reduction in the widespread use of existing technologies, 
within a health service in which funding and resources are ultimately limited.
Nevertheless, being leaders in the development of new technology platforms is important, for 
example, it offers:
• the option of early adoption and broader explotation of the underlying technologies;
• knowledge and skills for the more effective and efficient diffusion of related technologies (even 
where they are invented elsewhere);
• the option of staying out of the invention of the currently emerging technology, with the ability to 
jump in at a later stage, when a new or modified form of the technology becomes feasible.
15 While innovation generally refers to the “first use”, it is often qualified as being the “first successful use”, which, in some respect, allows the first use to be 
unsuccessful.  In addition, a distinction is often made between “global” and “local innovation”, where global refers to the first (successful) use anywhere in 
the world and local to the first (successful) use in a particular country (or even more locally, within a particular region, sector or enterprise).
16 The example of developing countries, which can often neither afford nor provide the skills for the early adoption of radical technologies, is an extreme case.
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However, being at the scientific17 forefront in the past has not always resulted in the expected 
down-the-line benefits for the suppliers of products and services to the health sector.  For example, 
while the basic research on MRI scanners is largely attributed to UK and US scientists (e.g. Peter 
Mansfield of Nottingham University and Paul Lauterbur, at that time a Professor of Chemistry at 
the State University of New York, who were jointly awarded the Nobel Prize), a current list of major 
producers of MRI scanners and closely related technologies18, suggests relatively few links between 
the original scientific work and the later distribution of production and employment.
Part of the problem with the more radical technologies is that their market exploitation (e.g. in the 
form of new products and services) often require knowledge and skills (e.g. Solo, 1966; Amsden, 
1989; for a recent review see Hanel, 2007) and that these might be more readily available in other 
countries (e.g. the US, Germany and Japan).
Solo (1966) was amongst the first to argue that the existence of formally educated scientific and 
technical elites is a necessary but not sufficient condition for the diffusion of new technologies and 
economic development.  Solo (1966) argued that sustained development can only take place when 
the skills of the middle mass of “mechanics and technicians” reaches a sufficient threshold.  Amsden 
(1989, p. 9) takes up this argument in the context of the “take-off” of Korean economy, pointing out 
that, while “[S]alaried engineers are a key figure in late industrialization because they are the gate 
keepers of foreign technology transfers”, nevertheless “... Korea was a successful learner [of foreign 
technology] partly because it invested heavily in education ...” (ibid. p. 23).
Incremental technological advances, which are often the successor to earlier more radical 
technologies19, are themselves a source of growth and employment.  In the case of incremental 
technologies, the knowledge and skills implications may be more modest than in the case of radical 
technologies.  Insofar as such technologies are more readily adopted and diffused amongst existing 
companies, their potential for generating employment, alongside a more modest rate of increase in 
skills may nevertheless produce significant benefits for the economy. 
The third point, which relates to the role played by existing technologies, is that the nature of 
technology life cycles often means that more mature technologies often provide more employment 
opportunities than new technologies.  The slow (if increasing) initial uptake of radical technologies 
means that they tend to create relatively little employment in the early phases and, what employment 
there is, tends to be relatively specialised and highly skilled (although, by implication, relatively well 
remunerated).  Existing, mature technologies may still employ more individuals than even radical 
new technologies, until the final phases before their demise.
17 Even being at the technological forefront does not guarantee success in the example of the eventual “victory” of VHS over Betamax video storage.
18 http://www.ebyte.it/library/NmrMriCompanies.html#mrioemscanners.
19 See Schumpeter’s wave of, on balance, increasingly more minor inventive and innovative activity, that follows in the wake of the introduction of some 
radical new platform, but which stimulates an upturn in the economy that only slows when the potential of the new area of technology becomes “mined out” 
(Schumpeter, 1949, p. 230).
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What is extremely important is that the changing mix of technologies and the employment opportunities 
they give rise to needs to be monitored and, to some degree, controlled to ensure that the jobs on 
offer at each point in time broadly require the skills supplied to fill them, bearing in mind the capacity 
to train and up-skill.  The aim would be to produce a changing mix of technologies and jobs over time 
that allow the economy to be on a rising skills (productivity and income) profile.  The implication of 
these arguments about existing technologies and incremental improvements is not that radically new 
technology platforms should be ignored – they are potentially of enormous future importance, but 
their introduction and diffusion needs to be managed in the light of the contributions of incremental 
technological advances and the gains from managing the decline and, eventual, demise of existing 
technology platforms (Bosworth, 2005, pp. 352-359).
4.3 R&D health spend
4.3.1 Domestic R&D
The evolution of R&D spend in the area of health is set out in an Excel workbook by BERR.20 The 
results of this are reported in Figure 4.2. Two principal results are shown, which are both derived 
from a single series, which has a discontinuity in 1995-96, caused by the shift in scope of health R&D 
in order to include research activities of the NHS in more recent years.  Thus, the higher of the two 
series (which is probably the more useful) approximates the path of R&D including the work of the 
NHS and the lower of the two gives the corresponding result excluding the NHS.21 
Figure 4.2: R&D health spend as a proportion of all R&D
Source:  www.berr.gov.uk/files/file22056.xls. Note: estimated series (based upon data that include NHS expenditure from 1995-96 onwards and excludes it 
prior to this date).
20 SET Statistics.  UR0000000048-08-1-I/on. www.berr.gov.uk/files/file22056.xls.
21 This margining of the two series was carried out by projecting forwards and backwards the individual series without and with the NHS R&D respectively, to 
provide an overlapping observation, which was used in the adjustment of both series.  The estimated trend in the series which includes the NHS prior to 1995-
96 implicitly assumes that the NHS spend remains proportional to that of the non-NHS R&D spend; the estimated trend in the series which excludes the NHS 
spend after 1995-96 implicitly assumes that the non-NHS spend remains proportional to that of the NHS.
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A significant rise in the proportion of all R&D devoted to health over the first half of the period is clearly 
apparent.  The results suggest that the increase in this proportion slows and falls to zero just after the 
end of the 20th century and, if anything, the series itself begins to fall slightly after that point.  As a first 
approximation, it appears likely that, for the foreseeable future health R&D, including NHS activity, will 
form a substantial part of all R&D. probably at around 14-15 per cent of the total.  This conclusion is, in 
part, a qualitative assessment, based upon: the current growth in technological opportunities in health 
(supply push) and the aging population (demand pull); set against, other priorities which will also put 
demands upon the R&D budget, such as the need to develop “green technologies”.
4.3.2 US R&D
While health appears to be a priority area in the UK R&D budget, it is clear that the US spends much more 
on medical research – more than Europe does (and much more than the UK does).  Billing, et al. note that:
 “Yet no matter how the available data are analysed and compared, Bio-medical research funding 
in the USA is much larger than in Europe. Relative to GDP the USA non-market sector spent 
between 0.25 and 0.43 per cent in 2004 on Bio-medical R&D (depending on the way university 
research is included and on the data source used), compared with 0.17 per cent for the EU 15 
countries [in] the same year. The most credible estimate for the USA lies between 0.37 and 0.40 
per cent more than twice the European spending relative to GDP and almost three times the 
European spending when measure relative to the size of the population. (Billig, 2007)
Figure 4.3 compares the research spending in the US, Japan and the EU 15 countries relative to 
1995 spending.  The relative amount of spending in the US is increasing more rapidly than in Europe 
and Japan and the US was spending more on R&D to begin with.
Figure 4.3: Trends in nominal medical research expenditures in national currencies
 
 
 
 
 
Source: Billig, H., et al. (2007, p. 19).  Note: R&D performed in the non-market sectors, relative to 1995 levels (=100).
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The amount of US spending on Bio-medical research between 1994 and 2003 is shown in Figure 4.4 
below.  According to Moses, et al. (2005),
 “Bio-medical research funding increased from $37.1 billion in 1994 to $94.3 billion in 2003 and 
doubled when adjusted for inflation” (Moses, et al. 2005, p. 1333).
The majority of this spending (between 56 to 61 per cent) comes from industry and the rest from the 
US government (ibid. p. 1335).
Figure 4.4: Funding for bio-medical research by source, USA, 1994-2003
 
 
Source:  Moses, et al. (2005, p. 1336). 
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4.4 Patenting Activity: broad technological trends
4.4.1 Interpreting patent statistics in the context of the changing economic climate
Figure 4.5: NASDAQ Composite Index 1983-2002
 
While there is a large amount of potentially informative patent statistics about the evolution of different 
areas of technology, the most recent technological trends are made more difficult to decipher by the 
recent economic downturn and, in the case of the technologies of interest here, the “dot-com bubble” 
(see Figure 4.5).
The problem is that, while the recent economic downturn has, broadly speaking, had a broad 
ranging effect on all activity, including R&D and patenting activity, the “dot-com bubble” was much 
more “technology specific” involving the more speculative areas of both research and commercial 
activity.  Thus, the speculative bubble of (roughly speaking) 1998-200122 had a differential effect on 
IT, biotechnology, genetic engineering and a number of other areas of technology central to future 
health provision.  The speculative bubble peaked in March 2000 and the market was still in decline 
through the early part of the 21st Century.  It was further overtaken by the growth in real oil prices and 
the worldwide crisis and recession caused by the failure of financial markets.  At the time of writing, 
the recovery from the failure of financial markets is still on-going, but the period covered will be at 
least 2007 to 2009/10, with some commentators predicting recurring problems beyond that period.
22 http://www.stock-market-crash.net/nasdaq.htm.
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As a consequence, while the many of the patent areas of considerable interest to health are still 
viewed as having enormous technological potential and commentators still believe that they will 
radicalise the provision of health services in the future, they are severely affected by these recent 
economic events.
The current discussion of longer term trends in patenting activity initially includes discussion of broad 
areas of technology of relevance to health.  Appendix 2 provides further information on the use patent 
data.  The data are taken from the OECD statistics portal23, and include series for biotechnology, 
micro-organisms, information communication technologies (ICTs), medical preparations and nano-
technology.  ICTs are included for completeness, as they are a general purpose technology (GPT) 
with fundamental implications for the development of technology in the other areas of health.  Finally, 
there is a brief discussion of the trends in nano-technology, which is an area that also appears to 
have significant implications for health, particularly in the medium to long term.
4.4.2 Life Sciences/Biotechnology
In this Section, the term “life sciences” is used to refer to the manipulation of cellular, sub-cellular, 
or molecular components in living things.  The IPCs that fall under this definition coincide with those 
listed under the “biotechnology” area in the OECD’s patent data. Thus the terms life sciences and 
biotechnology are used interchangeably in this section.  In order to see what technologies the OECD 
definition of biotechnology includes see van Beuzekom and Arundel, 2009).  
Figure 4.6a sets out the changing level of patent applications to the European Patent Office (EPO) 
in the area of biotechnology, based upon the OECD compiled statistics (again, see van Beuzekom 
and Arundel, 2009).  The strong upward trends through to about 2000 are followed by a levelling-off 
and, then, a fall in activity.  The minor upturn in 2006 seems likely to eventually be replaced by a 
further downturn as the financial crisis and the consequent world recession bite.  US activity appears 
to have been particularly adversely hit by the dot-com bubble, while the Japanese activity, which is 
a relatively small proportion of the total, is less significantly affected.
Figure 4.6b provides the cumulative totals of the data that appear in Figure 4.6a.  All of the series 
except for Japan suggest the exponential period of advance in this area of technology may have 
been coming to an end by the late 1990s, even before the dot-com bubble burst.  Given the size of 
patenting activity in this area and the size of technical know-how that has been accumulated over the 
years, this will, nevertheless, remain an important area of technology and technological advance for 
some time to come.  In addition, care needs to be taken that the perceived rate of diminution of the 
advance in biotechnology at the margin is a real one, and not an artifact of any special economic or 
political influences on that sector.
 
23 http://stats.oecd.org/index.aspx.
47
Strategic Skills Needs in the Bio-medical Sector
Figure	4.6:	Number	of	patent	applications	filed	at	the	EPO	in	biotechnology	between	1985	and	
2006, by geographical location of the inventors 
Figure 4.6a: Biotechnology (number)
 
Figure 4.6b: Biotechnology (cumulative number of all patent applications)
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Figure 4.6c: Biotechnology (per cent of all patent applications)
 
Finally, Figure 4.6c reports the corresponding percentages of biotechnology activity (as a proportion of 
total patent applications for each of the geographical areas).  The fall in activity at the end of the dot-com 
boom is, again, perhaps not surprising, although the size of the impact on the biotechnology area is; by the 
end of the period, the proportion for the US was not far off its 1985 level (at under 8 per cent of all US EPO 
patent applications).  There appears to have been a significant reassessment of the relative importance 
of biotechnology as an area of technological effort and technological change, particularly in the USA, 
but also in the EU.  While Japan does not appear to show the same degree of change, particularly with 
regard to the dot-com bubble (Japan had its own financial crisis in the latter part of the 20th Century), 
biotechnology applications formed a smaller proportion of its EPO patenting in 2006 than in 1985.
The class C12N, “micro-organisms”24, is a particulary important area of biotechnology.  As this class 
includes patents relating to stem cells, tissues and genetic engineering, it was decided to examine this 
class in slightly more detail.  Figures 4.7a – 4.7d show the patenting trends in micro-organisms.  The 
overall patterns in application activity (Figure 4.7a) appear to be similar to those for biotechnology in Figure 
4.6, with perhaps two important exceptions.  First, if anything the growth to the peak and the subsequent 
decline after the dot-com bubble are even steeper than in biotechnology as a whole.  Second, the peak in 
micro-organisms activity appears to be more closely associated with the dot-com bubble.  Nevertheless, 
there is no real sign of recovery through to 2006 (after which the effects of the financial crisis may produce 
a further negative effect).  At this stage, it appears that there has been a downward re-evaluation of the 
future prospects of technological advances in the micro-organisms area.
Figure 4.7b shows the cumulative amount of patenting activity, which confirms the discussion in 
the previous paragraph.  There appears to be exponential growth in patent applications in micro-
organisms up to and including 2001, but the upward trend after that suggests a sgnificantly slower 
rate of accumulation of technology in this area.  There is some evidence that the more adverse 
situation can also be found in Japan, but perhaps starting in 2003 rather than 2002.
24 The term “micro-organisms” is a catch-all – see below.
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It is clear from Figure 4.7c that this pattern is not just the effects of the economic situation on patent 
activity as a whole, as the proportion of micro-organism patent applications within the total of all 
patent applications also shows the same pattern.  As in the case of biotechnology, Japan appears 
to be largely immune from the impact of the dot-com bubble, while, if anything the USA is more 
severely affected in the case of micro-organisms than in the case of biotechnology (by the end of 
the period, the US has a smaller number of EPO applications in this area than the EU – see Figure 
4.7a).  Again, the relative down-turn in activity appears to take place in Japan beginning in 2003 
rather than 2002.
As C12N includes such a diverse range of technologies25, its subclasses were examined to see if 
all aspects of the class follow the same patterns as micro-organisms and biotechnology as a whole. 
This more detailed data concerns patent applications filed to the U.S. patent office which published 
in 2003 and 2008.26 
As Figure 4.7d shows, the number of published patent applications in micro-organisms declined 
between 2003 and 2008. The decline was particulary dramatic in the three largest subclasses: 
C12N1 (micro-organisms), C12N9 (enzymes) and C12N15 (genetic engineering)  There was a small 
increase between 2003 and 2008 in the C12N5 subclass which relates to cells and tissues and 
includes stem cell technology.
Figure	4.7a	 -	c:	Number	of	patent	applications	filed	at	 the	EPO	between	1985	and	2006	 in	
micro-organisms, by geographical location of the inventors
Figure 4.7a: Micro-organisms (number)
 
25 The subclasses within C12N and their subject matter are: C12N1 micro-organisms, culture media therefor; C12N3 spore-forming or isolating processes;  
C12N5 undifferentiated human, animal or plant cells, tissues, cultivation or maintenance thereof, culture media therefor; C12N7 viruses; C12N9 
enzymes; C12N11 carrier-bound or immobilised enzymes and carrier-bound or immobilised microbial cells, preparation thereof; C12N13 treatment of micro-
organisms or enzymes with electrical or wave energy;   C12N15 mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors.
26 Future work will explore the consistency of the results between the EPO and USPTO patent routes.
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Figure 4.7b: Micro-organisms (cumulative number)
 
 
Figure 4.7c: Micro-organisms (per cent all patent applications)
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Figure 4.7d: Number of published U.S. patent applications in 2003 and 2008 within micro-
organisms by subclass
4.4.4 Medical Preparations and Pharmaceuticals
The pharmaceutical patent technologies analysed here include medicinal preparations (class A61K) 
and the therapeutic activity of chemical compounds (A61P).27 
This is a very active area both in terms of the number of patent applications (Figure 4.8a) and in 
terms of the percentage of total patenting activity that it comprises (Figure 4.8b).  It is clearly an area 
of considerable importance to the UK, given the role played by pharmaceutical companies within 
the domestic economy.  However, it is also an area which appears, at least based upon trends over 
the last couple of decades, to be experiencing dminishing returns to R&D, perhaps because of the 
falling magnitude of technological opportunity in this area (e.g. the early evidence of Ballance, et 
al. 1992, p. 94-95).  Nevertheless, despite the effects of the dot-com bubble, the overall trends in 
numbers of patents have been upwards for the different geographical blocs (see Figure 4.8a).  While 
Figure 4.8b, which shows the cumulative total of EPO patent applications for medical preparations, 
shows a distinct “kink” in the curves around 2002 for all of the geographical areas (although less so 
for Japan than the others), this change in trend caused by the dot-com bubble bursting is somewhat 
less severe in nature than in the case of biotechnology and micro-organisms.
27 There is some overlap between the patents classified as pharmaceuticals and as part of biotechnology because the A61K technology group as a whole 
contains some areas that could be classified as part of the biotechnology caterogy (e.g. genetic medicines).  However, these subclasses make up only a small 
part of A61K so we analyzed the class in its entiriety here.
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Figure	4.8:	Number	of	patent	applications	filed	with	the	EPO	in	medical	preparations	between	
1985 and 2006, by geographical location of the inventors
Figure 4.8a: Pharmaceuticals (number)
 
 
Figure 4.8b: Pharmaceuticals (cumulative number)
 
53
Strategic Skills Needs in the Bio-medical Sector
Figure 4.8c: Pharmaceuticals (per cent all patent applications)  
The proportion of total patenting activty formed by pharmaceuticals, although growing through much 
of the period, did so at a diminishing rate (Figure 4.8c), and finally showed some signs of falling 
overall following the dot-com crisis (though not in any way like biotechnology as a whole or micro-
organisms).  This is confirmed by fitting polynomial functions to the various areas which reflect 
the medium to long term trends.  The results suggest that the proportion of patent applications 
attributable to this area has been growing roughtly linearly in Japan, but growing at a diminishing 
rate in all the other geographical blocs (a cubic trend line has been incorported in Figure 4.8c for the 
US to illustrate this point).
4.4.5 Medical technologies
In this section, medical technologies are defined by the international patent classes:
• A61B (diagnosis, surgery, identification);
• A61C (dentistry);
• A61F (prostheses, medical technologies, bandages, dressings);
• A61G (transport, personal conveyances or accommodation specially adapted for patients 
or disable persons and operating tables and chairs);
• A61H (physical therapy apparatus);
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• A61J (containers specially adapted for medical or pharmaceutical purposes, devices or methods 
for administering medicines);
• A61L (methods or apparatus for sterilising materials, bandage, dressings, absorbent pads, 
surgical articles); 
• A61M (devices for introducing media into or onto the body and devices for taking media from the 
body such as covers suction, pumping or atomising devices for medical use);
• A61N (therapy, ultrasound therapy).
It can be seen from Figure 4.9 that this is a major area of technological activity, which has increased 
significantly in importance over the period since 1985.  What is not immediately apparent from just 
looking at the figure is that the most rapid increase over the period was associated with Japanese 
applications (the 2006 value was just under 9 times larger than the 1985 value), although Japan 
started from a very low base.  The rate of growth of US applications outstripped that of European 
applications, but, while the US was more active by the end of the period than Europe, the two 
geographical blocs exhibited broadly similar magnitudes of activity by that stage.
Figure	 4.9:	 Number	 of	 patent	 applications	 filed	 at	 the	 EPO	 in	 medical	 technologies,	 
by geographical location of the inventors
Figure 4.9a: Medical technology applications (number)
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Figure 4.9b: Cumulative medical technology applications (number)
 
Figure 4.9c: Medical technologies (per cent of all patent applications)
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The data for all of the geographical areas in Figure 4.9a suggest that this is an area of technology 
where patenting activity is increasing strongly year on year.  This is confirmed by Figure 4.9b, which 
shows the cumulative number of patent applications for the same group of countries.  The shape of 
the curves suggests that medical technologies are still in the “expansionary phase” of the sigmoidal 
curve normally associated with the development and exploitation of any given area of technology.
Further evidence of the growing importance of the medical technologies sector can be found in 
Figure 4.9c, which shows the proportion of each geographical area’s patent applications to the EPO 
that fall in the medical technologies area, as defined above.  In the case of the USA, for example, 
medical technology applications formed nearly 12 per cent of all US applications to the EPO in 
2006 (provisional estimates for 2007 suggest that this rises to 12.6 per cent in 2007).  While the EU 
leads Japan in terms of the overall percentage of EPO patent applications associated with medical 
technologies, the rate of increase was faster for Japan.
Given the overall importance and relatively positive features of technological advance in this area, 
Figures 4.10a - 4.10d explore some of the areas of medical technology in more detail.  These four 
areas are: diagnosis surgery identification (class A61B); filter, prostheses, bandages, dressings and 
first aid kits (A61F), devices for introducing media into, or onto, the body ; devices for transducing 
body media or for taking media from the body (A61M) and ultrasound therapy and other similar types 
(A61N)  While some of these areas appear to be associated with “lower”, if new, technology (e.g. 
bandages and dressings), in some sense, this requires further investigation and, even if this proves 
to be the case, it does not mean to say that there is not a profitable market for new products based 
upon these technologies (and associated employment opportunities).  In addition, it should be noted 
that this group includes a number of recognised high technology areas, such as various kinds of 
scanners used in the diagnosis of illnesses and diseases.
One other feature of Figures 4.10a - 4.10d is the growth in activity in these areas by the USA relative 
to the other countries (with the exception, perhaps, of A61M).  The other notable feature is that, 
while Japan tends to show patterns similar to other areas of technology outlined above in three of 
the areas of medical technology, it shows quite a distinctive pattern in, A61B, the area of “diagnosis, 
surgery, identification, etc.”.  This area of technology becomes more important in Japan (vis a vis 
other areas of technology) than in the EU by the end of the period.
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Figure	4.10:	Patent	applications	filed	at	 the	EPO	in	medical	 technologies,	by	geographical	
location of the inventors (per cent)
Figure	4.10a:	Diagnosis,	surgery,	identification	(A61B)
Figure 4.10b: Prostheses, medical technologies, bandages, dressings, ... (A61F)
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Figure 4.10c: Devices introducing media into/taking media from the body (A61M)
Figure 4.10d: Devices for therapy, ultrasound therapy, … (A61N)
 
 
4.4.6 Information Communication Technologies (ICTs)
While ICTs do not fall within the biotechnology, pharmaceuticals and medical technology, nevertheless, 
it is clear that many developments in health technologies are related to advances in ICTs.  Obvious 
examples of this type include the scanning technologies that have emerged to radicalise the 
diagnosis of various health conditions, and the incorporation of wireless communications in medical 
technologies.  Figures 4.11a to 4.11c show the corresponding numbers and percentages for ICTs 
that were discussed for health technologies.
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While ICTs were at the heart of the dot-com bubble, Figure 4.11a suggests that technological advances 
in this area have not been affected to the same extent as most areas of health technology, such as 
the areas of biotechnology and micro-organisms.  There appear to be at least three reasons for this: 
first, although it is not immediately apparent why, the extent and nature of Japanese technological 
advance does not appear to have been so adversely affected as that of other geographical blocs by 
the dot-com bubble, especially the USA; second, ICTs are both heavily influenced by Japan and also 
form a high proportion of Japanese technological activity; third, ICTs form a GPT (general purpose 
technology) which remains both crucially important and potentially profitable in the medium and long 
term future, mitigating against any short-term adverse effects, such as the dot-com crisis.
Figure 4.11b demonstrates that the cumulative trends in ICT applications show an exponential pattern, 
with no obvious indication of any “turning-point” that would indicate a diminution of technological 
advance in this area over time.  Interestingly, all three geographical blocs have cumulative series 
which are very similar, with the EU surprisingly overtaking the USA (which is almost certainly a 
feature of using EPO patent applications rather than US or PCT patent data).
Figure 4.11c shows the importance of ICTs relative to all patenting activity for each of the three geographical 
blocs and for the World and OECD countries as a whole.  What stands out is the Japanese focus on 
ICT technologies; ICTs patent applications form between 40 and 50 per cent of all Japanese patent 
applications at the EPO.  The proportion of ICTs within the total is also higher for the US than for the EU. 
While the Japanese focus on ICT technologies is a major strength during the period that ICT advance 
remains in its “expansionary phase”, it may also be a major source of problems if Japan has to switch its 
focus to other areas of technology as the area of ICT advance matures.
The corresponding trends in nano-technology are shown in Figures 4.12a to 4.12c.  The field of 
nano-technology is in its relative infancy, so its application to advances in health technology are one 
step further removed.  Nevertheless, nano-technology appears to have the potential to create radical 
new opportunities for advances in health technology in the medium to long term.
While the minor jumps in the series, both down and up, at the end of the period will have had 
some effect, the overall picture from looking at cumulative patent applications is one of expontential 
growth (see Figure 4.12b).  The rapid increasing in patenting activity in nano-technology in the 
second half of the 1990s has the effect of driving the cumulative series upwards even more steeply. 
While growth in annual activity has slowed since then, the overall picture in the cumulative series is 
strongly upwards.  This, therefore, appears to be a technology in the early, exponential stages of its 
technological advance.
All of the geographical regions show some sign of a slowing or even a slight downturn around 
2001, however, this is, again, clearest in the case of the US.  Nevertheless, based upon polynomial 
functions of up to power 3 (see Figure 4.12c)28, the medium to long term projections would still be for 
increasing rates of activity in this area, with nano-technology becoming a relatively more important 
area within the total of all technologies.
28 Higher powers than 3 begin to pick up the downturn at the end of the series.
60
Strategic Skills Needs in the Bio-medical Sector
Figures 4.11 and 4.12: EPO patent applications in complementary technologies
Figure 4.11a: ICTs (number)
          
Figure 4.11b: ICTs (cumulative number)
 
Figure 4.11c: ICTs (per cent all patent  
applications)
Figure 4.12a: Nanotechnology (number)
          
Figure 4.12b: Nanotechnology (cumulative number)
 
Figure 4.12c: Nanotechnology (per cent  
pat applications)
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4.5 Conclusions
This chapter has provided a preliminary investigation of the patterns of technological change in the area of 
bio-medicine.  Ideally, it would have said more about the diffusion of existing and likely future technologies, 
along with the resulting skills implications.  Given the present state of the empirical literature and data 
sources, the present chapter is largely restricted to looking at recent trends in technology to examine:
• which appear to be the broad areas of technological opportunity for the future;
• to what degree are different geographical zones well placed to be at the forefront of such areas; 
and, in combination with later parts of the present report;
• what is the likely match between these technology areas and, at a broad level, the existing skills 
and knowledge base of UK industry, bearing in mind the absorptive capacity of the workforce for 
upskilling in new areas of technology.
Before turning to some sector-specific issues, there are some general conclusions that can be drawn 
from the present analysis:
• “bio-medical” technologies, as defined above, are a major area of R&D and technological activity, 
driven partly by the growing demands for (and on) health care services (e.g. as populations round the 
world become richer, as individuals live longer, etc.) and (in certain newer areas of technology), by 
technological opportunity and by (often currently ill-defined) future commercial applications;
• the size of the global effort in the advancement of bio-medical technologies is extremely large 
and, hence, international competition to be at the forefront of many of the associated areas of 
technology is intense:
 • in many of the areas, the USA is not only the country which dominates in terms of R&D and 
 patenting activity, but also shows the strongest upward trends, reflecting its effort to be the 
 technology leader;
 • there are exceptions to this “rule”, such as ICTs, where Japan still appears to be concentrating a 
 considerable part of its efforts – but, ICTs have such a pervasive range of applications, that Japan 
 seems likely to benefit from the growth of other areas (such as medical scanner technologies) 
 without the need to be leader in other aspects of the technology;29 
 • the EU is often a secondary player to the USA, although often showing some advantage over 
 Japan.  As the UK is a small (though important) player within the EU as a whole, the implication 
 appears to be that the UK not only needs to find technological niches where it will have a 
 comparative advantage, but also a strategy with regard to the optimal adoption of technologies 
 produced elsewhere, including outside of the EU;
29 Although the application of ICTs to other areas (such as scanners) might also give Japan a door by which it might enter into these technologies at other levels.
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 • certain areas of technology have been particularly impacted by the effects of the “dot.com 
 bubble” (e.g. micro-organisms) and have yet (if they ever do) recover to the earlier levels of 
 activity30.  Interestingly, the patterns of change for ICTs seem little affected by the bursting of the 
 “bubble”, as does the overall activity of Japan, which tends to specialize in ICTs.
At a “sectoral level”, the results of the present work boil down to addressing a small number of 
dynamic structural issues, in particular, two that will be highlighted here:
• despite the significant forces for change faced by the pharmaceuticals sector, it remains a major 
employer within the UK, both in terms of its high-level technological activities (e.g. R&D), but also 
in terms of the number often less-skilled production jobs that it currently gives rise to – jobs that 
are particularly at risk of going abroad as part of the general pattern of globalisation;
• the automobile sector as a whole (both assembly and the associated supply chain) is experiencing 
a shift in production away from the UK, again as part of the general globalisation process.  While 
this is part of a longer term trend, it has been accentuated by the recent financial crisis and 
resulting recession, hitting certain areas (e.g. the West Midlands) particularly hard, and resulting 
in the loss of skilled jobs, whose previous incumbents are often either unemployed or moving into 
lower skilled employment;
• while the evidence suggests that there has been, over recent decades, a massive increase 
in patenting activity in biotechnology, the data also suggest that this trend is sensitive to the 
investment climate.  Following the bursting of the dot com bubble in the early 2000s patenting 
activity fell away though it has picked up again recently.  Given the pace of scientific endeavour in 
this field and the level of R&D investment to translate scientific breakthroughs into products this 
would appear to be most promising area of activity.  From an employment perspective, it is not 
clear whether this will feed into large-scale or niche manufacture;
• the medical technologies sector is one where there have been relatively strong levels of patenting 
activity over recent years.  Many of the activities here are engineering related which has potential 
to create employment in the engineering sector in the UK.
The question arises as to whether the technology trends outlined in this section throw any light on 
these two “structural problems”.  Whilst not wanting to overstate the case, based upon an initial 
investigation of the R&D and patenting evidence, it does seem possible to draw some useful 
conclusions about these two issues:
• despite the problems reported by the pharmaceuticals sector (including the apparent, long-standing 
trend in diminishing returns to R&D), patenting activity has continued to increase for much of the 
period since 1985.31 It is only in the period since 2001 that the rate of increase appears to have 
30 The effects of the financial crisis and the associated global recession lie at the very end of the period of study and nothing of substance can be said about 
their effects on technological activity at the present time.
31 Again, corroborative evidence needs to be sought outside of the EPO data, for the USA PTO and other sources..
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slowed, which may be simply a reflection of the dot.com bubble or it may be something more 
long-term.  There is, however, probably considerable life left in the pharmaceuticals sector yet 
and the loss of the leading technological role that this sector plays in the UK would have serious 
consequences for the UK science base.  In addition, the loss of this leading role would almost 
certainly accelerate the demise of the more commonplace production activities of the sector, with 
accelerated job losses to China, India and other developing countries;
• perhaps the most surprising result, at least to the research team, was the level and growth of 
technological activity in the medical technologies area.  This is an area where, broadly speaking, 
whilst some way behind the USA, the EU may be within “striking distance”.  While there are clearly 
a number of very high technology areas, where countries such as the US and Germany have an 
important lead, many of the technologies are less clearly at the cutting edge of science, and may 
be associated with new products and processes that could be produced in the UK, where there 
may be a readily available supply of suitable skills if enterprises could be encouraged sufficiently 
to move into this area. The potential, for example, of firms in the automotive supply chain in the 
UK to capture this market is particularly considerable (Hogarth et al., 2005).
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5.1 Introduction
This chapter is concerned with current and future skill demand in the bio-medical sector.  It draws on 
evidence from the Working Futures database – a specially constructed time-series of data relating 
to the bio-medical sector - and a variety of surveys which have been conducted in various sub-
sectors.  It should be stated at the outset that some of the surveys conducted provided relatively little 
evidence about the population of employers they have surveyed or the extent to which the survey is 
representative of that population.  Nevertheless, by comparing a number of sources it is possible to 
identify some common trends across the sector with respect to current and future skill demand.
5.2 Working Futures Projections of Employment Demand
In order to provide a consistent set of estimates of current and future skill demand in the bio-medical 
sector, a time series of employment was created from the Working Futures time series.  Working 
Futures provides a historical time series dating back to the early 1980s, and projects the future 
employment demand to 2017.  Though the projections were prepared just as the scale of the current 
economic downturn was becoming apparent, they still provide a robust view of trends over the 
medium-term.
An employment time series was produced for the following sub-sectors:
• Manufacture of  basic pharmaceutical products;
• Manufacture of pharmaceutical preparations; and
• Manufacture of medical, surgical and orthopaedic equipment.
This provides a partial coverage of the sector as described in Section 1.3 but nonetheless is likely to 
contain the majority of people who work in the bio-medical sector.
Figure 5.1 shows the overall employment trend between 1981 and 2017 based on a series derived 
from the Working Futures database.  In 2007, it is estimated that 79,000 people were employed in 
the sector overall in England.  Of this, 27,000 were employed in medical technologies and 52,000 
in pharmaceuticals.  Based on data reported by BIS (see Chapter 2), an upper estimate of total 
employment in England would be around 110,000.  If one were to take a mid-point estimate, this 
would suggest around 95,000 people employed in the bio-medical sector in England.
5 Current and Future Skill Demand
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The general trend - derived from the Working Futures database - is for employment to decline gradually, 
especially so in medical technologies, but much less so in pharmaceuticals.  Table 5.1 summarises 
employment change across the sector and reveals that employment in the pharmaceuticals sector has 
been, and is expected to continue to, fairly stable over the forecast period, with most of the employment 
loss attributed to medical technologies.   It should be noted that these data ignore replacement demands 
which, as Working Futures demonstrates, tend on balance to be positive over the medium-term.
Figure 5.1 Employment Trends in Pharmaceuticals and Medical Technologies
 
Source: Working Futures Database
 
Table 5.1 Total Employment Change in Pharmaceuticals and Medical Technologies in England, 
1997-2017
Source: Working Futures Database
1997 2002 2007 2012 2017
All Bio-medical 
Manuf. basic pharmaceutical products 
Manuf. pharmaceutical preparations 
Manuf. medical, surgical and orthopaedic eqpt
85 
10 
37 
38
95 
13 
50 
32
79 
11 
41 
27
76 
11 
42 
23
72 
12 
41 
19
Growth Rates
1997-2007 2007-2012 2012-2017
Per cent pa 
All Bio-medical 
Manuf. basic pharmaceutical products 
Manuf. pharmaceutical preparations 
Manuf. medical, surgical and orthopaedic eqpt
 
-0.6 
1.3 
0.9 
-3.4
 
-0.8 
0.8 
0.5 
-3.0
 
-1.1 
0.1 
-0.3 
-3.3
Change (000s)
 1997-2007 2007-2012 2012-2017 
Change *=(000s)  
All Bio-medical 
Manuf. basic pharmaceutical products 
Manuf. pharmaceutical preparations 
Manuf. medical, surgical and orthopaedic eqpt
 
-5 
1 
3 
-11
 
-3 
0 
1 
-4
 
-4 
0 
-1 
-4
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Figure 5.2 shows the occupational structure in the bio-medical sector both currently and how it is 
expected to change over the medium-term.  It is immediately apparent that while much of the debate 
is about the demand for highly qualified managers and scientists on which the future development 
of the sector depends, much employment is also concentrated in relatively less skilled occupations 
related to skilled trades and machine operatives.  Skilled trade occupations, especially those allied to 
engineering, are often ones in which recruitment problems are fairly common.  So there is a need in 
considering the skill needs of the sector to bear in mind that there is a requirement for a large number 
of intermediate and lower skilled people.
Figure 5.2 Structure of Employment in the Bio-Medical Sector
 
Source: Working Futures Database
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The overall pattern of occupational change is provided in Figures 5.3 to 5.5 which show that it 
is amongst the higher level occupations, notably managers and science professionals, in which 
employment is expected to grow over the medium-term.  In medical technologies the overall pattern 
of change is for total employment across all occupations to be in decline over the medium-term.
Figure 5.3 Occupational Change in the Pharmaceuticals and Medical Technologies Sector, 
1981-2017
 
 
Source: Working Futures Database
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Figure 5.4 Occupational Change in the Pharmaceuticals, 1981-2017
 
Source: Working Futures Database
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Figure 5.5 Occupational Change in Medical Technologies, 1981-2017
 
Source: Working Futures Database
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Projections of future employment suggest that there will be an increased demand for people qualified 
at graduate and postgraduate levels across the economy (Wilson, 2008).   In particular a substantial 
increase in the number of people qualified to graduate and postgraduate levels in engineering and 
biological sciences will be required.  At a postgraduate level, an additional 112,000 people with a 
postgraduate qualification in Biological Sciences will be required (representing a 70 per cent increase 
between 2007 and 2017) and an additional 220,000 postgraduates in engineering.   This suggests, 
other things being equal, that employers in the bio-medical sector will face increasing competition for 
the highly qualified staff they need.  The available evidence reveals that it is common for the bio-medical 
sector to report a demand for substantial numbers of postgraduates.  In Medicon Valley in Denmark at 
the beginning of this century projections were being made of a huge additional requirement for people 
qualified to PhD level in subjects allied to the bio-medical sector (Thomsen, 2004).
In general, replacement demands are likely to be considerable across occupations in the bio-medical 
sector.  Figure 5.6 shows the age structure of the workforce and reveals that around a third may 
be expected to retire over the next ten to fifteen years.  Cogent in relation to the pharmaceutical 
sector expects the total level of replacement demand over the next decade to be around 27,000 (by 
2020 with around 60 per cent of this being concentrated in higher level occupations, 25 per cent in 
technical occupations, and 10 per cent in process occupations (Cogent, 2009).
Figure 5.6 Age Structure of the Bio-medical Workforce
  
Source: LFS, 2008 Q1-Q3
5.3	 Specific	Skill	Needs	in	Pharmaceuticals
Working Futures uses generic occupations to show how skill structures are developing, but there is 
also a need to look further into the specific skills which are emerging in relation to the sector interest. 
Based on a review of the literature a number of high level skills have been identified as being critical 
to the future success of the sector (see Table 5.2). Where information was available, or provided by 
stakeholders, an indication of the extent to which shortages are currently experienced is provided.
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Table 5.2 Strategic Skill Needs in the Pharmaceutical Sector
   
 
Skill set / discipline Level Shortages  
(where reported) 
Current Demand Future Demand
Biological Skills 
Clinical pharmacology/ 
translational medicine
Graduate 
PhD 
Post-doctorate
Relatively small 
numbers required, 
but demand is 
thought to be in 
excess of supply
Current demand 
as specified but is 
expected to grow in 
the future
In the future, 
depending upon 
the breakthroughs 
in biotechnology, 
these types of 
skill are likely to 
be increasingly in 
demand.
Pharmacokinetics/ADME
In vivo research skills
In vitro research skills
Toxicology
Pathology
Molecular biology
Biochemists Demand increasing 
with shift to 
biotechnology
Pharmacy Graduate Overall high 
level of demand 
currently
Trends expected to 
continue in future.  
Chemistry 
Spectroscopy Graduate
PhD
Post-doctorate
Generally 
considered hard to 
recruit by industry
Well rounded 
chemists 
considered to be 
difficult to recruit.
Demand from the 
Bio-medical sector 
will increase, but 
supply is also 
increasing.
Analytical chemistry
Synthetic chemistry
Physics 
Bio-medical imaging Graduate / post-
graduate
Whether shortages 
emerge in the 
future is dependent 
upon the increase 
in the number of 
physicists.  Physics 
has not proved 
as amenable 
to increases in 
the number of 
graduates as other 
science disciplines.
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Table 5.2 (continued) Strategic Skill Needs in the Pharmaceutical Sector
Source: SEMTA (2006); APBI (2009), Edwards (2007); IER Stakeholder Interviews
 
Skill set / discipline Level Shortages  
(where reported) 
Current Demand Future Demand
Mathematics & Statistics 
Statisticians Graduate Demand increasing
Strong demand 
from other sectors
Current demand 
strong and 
increasing
The demand for 
simulation and 
the increased use 
of bioinformatics 
will increase the 
demand for people 
qualified in these 
subjects.   This will 
need to be allied to 
an understanding  
the phenomenon 
they are studying
Simulation Graduate/PhD/ 
Post doctorate
Bioinformatics
In silico modelling
Engineering 
Chemical engineering Graduate Strong competition 
from other sectors
High labour 
turnover also 
depletes stocks
Not much 
evidence of severe 
shortages currently
The main barrier in 
the future may be 
that of attracting 
engineers into 
the sector – 
especially medical 
technologies
Instrument engineering/process 
control
Mixed (graduate/
non graduate)
“omics”
Multidisciplinary approaches 
including:
Genetics molecular biology, 
mathematics , IT, etc
Emerging 
discipline, but 
highlighted in the 
literature as a 
potential source of 
shortage
Skills sets just 
beginning to 
emerge
The multi-
disciplinary 
approach involving 
team work will 
become increasing 
to the fore
Generic Skills 
Scientific literacy Skills which need to be allied to technical disciplines – generally 
considered to be in short supply
In general employers report shortages of these type of skills
The demand for increasingly sophisticated generic skills may 
stimulate shortages
Leadership/management 
Quantitative skills
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Several of the stakeholders interviwed commented on the convergence of technologies and disciplines 
and the need for multi disciplinary teams to include engineers, bio scientists, bio engineers, data 
manipulation and ICT people, materials experts and people to work with living materials, electronics 
and design, regenerative tissue engineering, miniaturisation of devices – nano technology.  This 
multi disciplinary working environment raised a demand for communication skills.
The skill needs of the sector have been defined very much with respect to emerging technologies 
which, in many instances, are yet to develop into new products being brought to market.  Hence, 
the available data give no indication of the quantity of skills required, simply that more are required. 
It is also apparent that some of the skills required relate to disciplines or occupations (e.g. clinical 
pharmacology) whilst others relate more to generic, cross-cutting skills such in vivo research skills.
Data specifically for the biotechnology sector suggests that around 45 per cent of employment in 
this sector is in R&D jobs, compared to around 40 per cent in the USA and 50 per cent in Germany 
(Critical I, 2006).
5.4	 Specific	Skill	Needs	in	Medical	Technologies
At a strategic level the skill needs of the medical technology sector have been viewed with respect 
to the coalescence of skill in instrument engineering, IT, and biotechnology.  It is a sector which there 
is a range of high level skill needs which are depicted in Figure 5.7.  
Figure 5.7 Inter-industry linkages in Medical Technologies and Associated Skill Needs
 
 
Source: Medico/Sundhed – en erhvervsanalyse, Erhvervsfremmestyrelsen, 2001 (Denmark), based on the example of Medicon Valley
Bio technology
Information 
technology
Genetics
Bio computers
Bio informatics
High speed 
screening
Bio-imaging (3D)
Neuro informatics
Virtual laboratories
Consultations and 
hospitals
Personalised and 
individual prevention, 
diagnosis and 
prevention
E-health
Remote devices 
and diagnostics
Virtual reality
Robots/robot 
surgery
Nano technology
Instrument
technology
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Surveys of engineering companies in the West Midlands which were engaged in the production of 
goods with a medical application reveal this skill needs to be a little more generic (Hogarth et al., 
2004; Hogarth et al., 2005).  The skills employers For the most part, these related to:
• Basic computing skills;
• Engineering skills;
• Communication skills;
• Customer handling skills;
• Problem solving skills;
• Management skills;
• Medical device regulations;
• Experience of dealing with NHS;
• Numeracy skills;
• Literacy skills;
• Personal attributes;
• Technical/practical skills.
The critical skill sets which employers identified in relation to the constraints on business development 
in the medical technologies cluster are outlined in Figure 5.8.
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Figure 5.8: Critical skill needs in relation to medical applications and markets
Source: LSC/ESF Medical Technologies Skills Survey 2005 (IER/IFF); Hogarth et al., 2005 – 
 
In another, older study of the skill needs of the medical technology sector in the West Midlands Byre 
Associates sought to identify the skill needs and skills gaps in companies in the West Midlands 
medical technology sector and to map learning relevant provision in the region.  The study identified 
three main areas of need for medical technology businesses.  These were:
• medical engineering;
• project management; and
• new product development.
The report concluded that skills gaps were of secondary importance compared to other business 
issues (such as short-term profitability or the impact of legislation and industry regulation).  Insofar as 
skills development needs were identified, these needs were for supervisory and project management 
skills, business and commercial skills for technical managers and for Level 4 process and electronics 
engineering skills.  The report also concluded, after mapping provision in the region, that there was 
adequate provision in further and higher education institutions to meet the learning needs identified 
by companies in the medical technology sector.
The findings of the Byre Associates report are echoed to some extent in the findings of the ATL survey 
of medical technology businesses (cited in Gibney, 1998).  The ATL survey reported that employers 
in the medical technology sample identified a number of skills related weaknesses relating to:
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• an inadequate supply of professional engineers;
• a lack of production skills in the medical diagnostics/devices area;
• a general lack of bioscience skills in the region;
• a lack of knowledge of working directives and standards required for medical technology device 
manufacture and production;
• a shortage of laboratory technicians;
• a lack of entrepreneurs in the medical technology field.
5.5	 Specific	Skill	Needs	in	Biotechnology
Many of the skill needs mentioned in the medical technology sector are the same as those required 
in pharmaceuticals (see Table 5.3).  The nature of the biotechnology sub-sector – typically micro-
enterprises pursuing an innovative new idea – suggests that their skill needs are at a high-level and, 
often, at the cutting-edge of scientific progress (in vitro and in vivo research skills, pharmacokinetics, 
bioinformatics and simulation, etc.  Perhaps the key issue here is that there has been, with the shift 
towards the use of biological agents rather than chemical ones in pharmaceuticals, a significant 
shift in the science base.  This potentially creates a skill or professional development demand 
amongst those already working in the pharmaceuticals industry, and a requirement for an inflow of 
scientists and engineers with differing skills sets from previous cohorts.  It is easy to overstate this – 
biotechnology as a discipline has been around for several decades – but it has created a significant 
shift in skill demand.
5.6	 Skills	for	Diversification	into	Medical	Markets
In the pharmaceutical and biotechnology sub-sectors companies tend to be focused solely on 
pharmaceutical or biotechnology activities. This is not the case with medical technologies, where 
engineering companies are likely to be engaged in the production of a range of goods only some of 
which are medical related.  Indeed, some may have only recently diversified into the medical market. A 
survey of mainly engineering firms in the West Midlands revealed substantial potential for companies 
to diversify into medical technologies.  This tended to take the form of taking an existing process or 
product and modifying it so that it had a medical application (Hogarth et al., 2005).   The study found that 
over 50 per cent of current medical technology businesses had diversified into medical technologies 
since the business was first established.  This stands in contrast to medical biotechnology firms which 
tend to be established with the sole purpose of producing a medical application (Critical I, 2006a). 
Hence, there is considerable potential for companies, typically engineering ones but others too, to 
diversify into the production of medical technologies and equipment.  The West Midlands survey also 
revealed that around 20 per cent of businesses not currently engaged in the production of medical 
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technologies and equipment felt that their existing products had potential medical applications. This 
raises the whole issue of the strategic and tactical skills required to diversify into medical markets. 
The evidence suggests that where companies diversify into medical markets this can exacerbate 
any skill shortages, because the process of diversification tends to increase the level of skill demand 
in the organisation, principally in relation to engineering design skills.  In addition, knowledge of 
the NHS procurement system is also a barrier those diversifying into medical technologies need to 
surmount and, the West Midlands study revealed, this can be a substantial barrier.
5.7 Generic Skill Needs
There are a number of generic skill sets which emerge across both sub-sectors.  These relate 
principally to management and the skills managers need to acquire if they are sustain their position 
in the product market.  To some extent, the skills needed relate to product vision and obtaining an 
alignment between the needs of the product market and the capability of the organisation to respond 
to those needs.  These types of skill needs are common across most sectors.  At the cutting-edge of 
the sector this relates very much to being innovation driven.  There are a range of skill needs here 
relating to the capacity to lead multi-disciplinary teams.  Given the amount of outsourcing which now 
appears common across parts of the sector, especially in some of the high-value, cutting edge sub-
sectors, there are a range of management skills which relate to:
• managing a network of teams across companies and sometimes across countries to deliver to the 
specification;
• being able to deepen and strengthen relationships so that they deliver more than the sum of 
their parts.
For a large section of the sector this relates more to managing a relatively mature product in markets 
which are subject to strong price competition.  As noted in Chapter 3, parts of the sector are under 
considerable pressure to reduce costs.  The key management skills which emerge relate very much to:
• Lean management;
• Six Sigma32;
• design of new products which can use existing production machinery.  
There are also a set of skills which relate primarily to SMEs given their important role in developing new 
products in pharmaceuticals and biotechnology, and their critical mass in the medical technologies 
sub-sector.  Hence one of the stakeholders pointed out that bbusinesses, not least SMEs, lack 
strategic skills.  They are good at day to day survival but they are not good at forecasting the 
future; they are not good at identifying market opportunities; they don’t understand how the sector 
32 Six-sigma is a well established process in manufacturing for identifying errors and minimizing variability in production processes.
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works; they don’t know who the key decision makers are.  Another respondent pointed out that the 
difficulties for SMEs addressing marketing skills and the tendency to outsource marketing and sales 
representation, or to develop partnering arrangements for marketing and sales; but they typically 
then do not manage such partners well and become exposed to the vagaries of the quality of the 
partner skills and effort.
5.8 Conclusion
Chapters 3 and 4 revealed the direction of technological change in the bio-medical sector.   The data 
on skill demand demonstrates the more cutting-edge technological breakthroughs are dependent 
upon high level scientific skills in the biological sciences.  Indeed, much of the discussion about 
future skill needs in the bio-medical sector is based around, almost exclusively, developing a strong 
skill capability in the emerging areas of new therapies.   The study has tried to identify as far as 
possible what these skill needs are likely to be.  
While the skills allied to the latest technological breakthroughs are clearly important for the future of 
the sector in England, the review has also identified a more everyday, though important group of skills 
related to maintaining, or incrementally developing the existing range of products.    These relate to 
graduate level skills in biology and engineering but also intermediate level skills typically associated 
with skilled trades jobs.   The study has pointed towards the potential for, typically, engineering firms 
to capture an increased share of the medical technologies market but to do so they require the skills 
which allow them to enter this segment of the market.  These skills sets relate very much to acquiring 
the knowledge to navigate the NHS procurement system but also developing the engineering design 
skills to allow products to be adapted to the needs of the health service.  As chapter 3 revealed there 
is considerable potential for engineering and software solutions to be applied to a range of issues 
with which the health service is faced.
Though there is a clear distinction to be made between the skill needs of the cutting edge versus 
the more steady performers in the sector, the evidence as a whole points to the skill needs of the 
sector increasing, both qualitatively and quantitatively, over the medium-term with much of this being 
dependent upon having a technologically / scientifically literate workforce. 
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6.1 Introduction
The pace of technological innovation in the bio-medical sector is such that it places substantial 
pressures on the supply side to keep pace.  There appear to be both quantitative and qualitative 
changes in the demand for highly skilled people to work in the sector.  At the highest skill levels, the 
market for people is an international one with the best and most capable people attracted to centres 
of excellence around the world.  But the remainder of the workforce is unlikely to be so mobile hence 
the importance of creating and maintaining a local supply.
In general, there are two types of skills supply which are of interest:
 i. supply from the education system, especially higher education but not exclusively so; and
 ii. continuing professional development and training.
Available statisitical evidence on the supply side is quite limited, but it is possible to discern some 
key points.
6.2 Supply from the Higher Education System
Assessment of supply from the higher education system is based on: (a) the supply of people 
qualified in subjects germane to the medical technologies sector (mainly engineering related); and 
(b) the supply qualified in science subjects more generally and which are of particular relevance to 
the pharmaceuticals sector.  These data are indicative of the supply of people with the skills required 
by the bio-medical industry.
Figure 6.1 provides an indication of the trend in supply of people with degrees in subjects close to the 
interests of the medical technology sub-sector.  The general trend is one of supply in decline though 
the rate of decline is quite modest.
Table 6.1 shows the change in the number of people studying degrees in the range of sciences 
germane to the bio-medical sector over the period 2002/3 to 2007/8.  In contrast to the data relating 
specifically to medical technologies, the figures demonstrate that there has been an increase in the 
number of people taking these qualifications. This may be evidence that  students are responding to 
signals being sent by the market that there is a strong demand for people to work in the biosciences. 
In Biological Sciences, however, much of the growth relates to an increase in the number of people 
studying Sports Science and Pyschology which may be less directly applicable to the bio-medical 
sector than some of the other Biological Science degrees.
It should be also be noted that the industy is a major investor in educationand training with the 
pharmaceutical sector hosting around 670 PhDs each year (ABPI, 2008).
6 The Supply Side and Skills Mismatches
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In relation to the pharmaceutical sector, Cogent has noted that overall the pharmaceutical sector 
takes on about 1,300 graduates every year which represents a small fraction of the overall population 
of STEM graduates thereby indicating that increasing the supply of gradautes is a weak lever of 
direct supply to the industry (Cogent, 2009, p. 34).  This is a critical question: is the extent to which 
increasing the supply necessarily leads to more people entering sectors such as the bio-medical 
one.  An indication can be obtained from the extent to which people who hold, for instance, a degree 
in Biology are engaged in scientific employment. From a quantitative perspective the Biological 
Sciences has a fairly successful conversion rate of people qualified in Biology entering a scientific 
profession or assoicate profession (see Table 6.2), but the situation is much more varied in relation 
to other scientifc subjects. Of those with Biology degrees, 64 per cent were employed in scientific or 
health occupations, compared to 24 per cent of those qualified in Physics.
Figure 6.1 Number of People Graduating with First Degree Relevant to the Medical 
Technologies Sector
 
Source: BERR Medical Technologies Metrics; HESA
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Table 6.1 Students Studying Degrees Germane to Bio-medical Sciences, 2002/3 to 
2007/8 absolutes
 Total Number of Students 2007/8 Change 2002/3 to 2007/8
Total HE  
students
Full-time 
graduate
Full-time 
under-
graduate
Part-time 
post-
graduate
Part-time 
under-
graduate
Total HE  
students
Full-time 
post-
graduate
Full-time 
under-
graduate
Part-time 
post-
graduate
Part-time 
under-
graduate
Medicine & 
dentistry 
61810 7670 43820 10160 160 12895 10475 2210 205 5
Subjects allied  
to medicine 
287125 11690 143910 35165 96360 20710 12950 4400 7920 -4565
Pharmacology, 
toxicology & 
pharmacy 
21615 2775 13715 3950 1175 5955 3475 1490 300 690
Medical technology 8335 380 5445 1780 730 1740 1740 185 -450 265
Biological sciences 161600 16650 111690 9940 23320 35740 19350 3910 -2625 15105
Broadly-based 
programmes within 
biological sciences 
765 10 720 0 35 -260 -165 -55 -65 20
Biology 26360 3390 18405 950 3615 1950 1015 275 -1125 1785
Botany 620 335 195 25 65 -225 30 50 -105 -195
Zoology 3810 300 3390 30 90 -55 225 5 -145 -140
Genetics 2100 510 1480 75 30 -595 -310 -5 -260 -25
Microbiology 3375 655 2225 310 185 -820 -130 -290 -455 55
Sports science 32870 1060 29365 855 1590 15285 13610 535 145 995
Molecular biology, 
biophysics & 
biochemistry 
10315 2120 7280 360 555 1035 595 585 -390 245
Psychology 72570 7150 44625 6580 14215 21790 8830 2515 -35 10480
Others in biological 
sciences 
8815 1115 4005 760 2935 -2370 -4345 280 -185 1875
Veterinary science 4850 490 4080 225 55 1010 915 90 -15 15
absolutes
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Table 6.1 (continued) Students Studying Degrees Germane to Bio-medical Sciences, 2002/3 to 
2007/8 absolutes
 
 
Source: HESA statistics; own calculations 
Note: shaded cells show where numbers have decreased
Total Number of Students 2007/8 Change 2002/3 to 2007/8 
Total HE  
students
Full-time 
graduate
Full-time 
under-
graduate
Part-time 
post-
graduate
Part-time 
under-
graduate
Total HE  
students
Full-time 
post-
graduate
Full-time 
under-
graduate
Part-time 
post-
graduate
Part-time 
under-
graduate
Physical sciences 82130 13900 52685 3890 11655 11090 5175 1875 -2445 6485
Broadly-based 
programmes within 
physical sciences 
965 0 910 0 60 35 0 0 0 40
Chemistry 18815 4240 12515 310 1745 -200 890 -30 -1430 365
Materials science 620 340 255 20 0 185 30 185 -15 -20
Physics 14870 3225 10145 290 1210 2040 1100 630 -780 1090
Mathematical 
sciences 
34120 3600 22770 1520 6225 7930 3300 755 -1220 5090
Broadly-based 
programmes within 
mathematical 
sciences 
85 0 55 0 30 -450 5 0 0 -455
Mathematics 29620 2420 21045 935 5225 9500 4190 525 -45 4840
Operational research 855 355 415 80 5 40 -15 155 -55 -45
Statistics 3435 800 1215 495 930 -505 -465 240 -1010 740
Others in 
mathematical 
sciences 
125 30 40 15 45 105 20 30 15 45
Computer science 95575 13425 55700 6520 19935 -38460 -29835 -975 -3450 -4195
Engineering & 
technology 
139435 23875 80425 11800 23335 7860 3570 3825 -4690 5150
Chemical, process & 
energy engineering 
7715 1660 4405 1010 640 2130 1230 285 125 490
Biotechnology 1025 495 460 55 20 890 335 485 55 20
Economics 29850 5310 22155 725 1660 710 270 1060 -1350 735
absolutes
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Table 6.2 Occupational Characteristics of People with Science and Mathematics Degrees, 2007
 
Source: Labour Force Survey 2007; own calculations
Base: All with a current occupation
Degree Subject 
 
Biological 
Sciences 
excl Sports 
Science /  
Psychology
Other 
Physical 
Sciences Chemistry Physics
Mathematical 
& Computer 
Sciences Engineering All 
Corporate Managers 7 20 16 19 17 20 9
Managers & Proprietors 1 2 5 13 2 2 2
Science/Tech Professionals 2 19 0 6 19 31 3
Health Professionals 3 3 1 0 1 0 1
Teaching/Research Prof. 3 13 7 9 13 7 4
Business/Public service Prof. 2 5 4 0 7 6 3
Science/Tech Associate Prof. 1 5 2 4 4 4 1
Health Associate Prof. 54 1 0 2 2 1 3
Protective Service Occs 0 0 0 2 1 0 1
Culture/Media/Sport Occs 0 2 0 2 2 1 2
Bus/Public Serv. Assoc Prof. 2 6 24 10 7 5 4
Any kind of Science / Health / 
Teaching occupation
61 40 10 21 39 43 11
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From the supply side, available information suggests that in the fields of life sciences / medicine, 
three of the world’s top 20 universities are located in England, though most of the top 20 are based in 
the USA.  There is always disagreement about how these types of ranking are constructed but they 
nevertheless give an indication of the relative positioning of UK based universities (see Table 6.3).
Table 6.3 2009 Top 20 Life Sciences Universities
 
Source: http://www.topuniversities.com/world-university-rankings
Rank School Name Country 
1 Harvard University United States 
2 University of Cambridge England 
3 University of Oxford England 
4 University of California, Los Angeles (UCLA) United States 
5 University of California, Berkeley United States 
6 John Hopkins University United States 
7 University of Tokyo Japan 
8 Massachusetts Institute of Technology (MIT) United States 
9 Yale University United States 
10 Mcgill University Canada 
11 University of Toronto Canada 
12 University of California, San Diego United States 
13 University of Melbourne Australia 
13 Kyoto University Japan 
15 University of Sydney Australia 
16 University of British Columbia Canada 
17 Imperial College London England 
18 University of California, Los Angeles (UCLA) United States 
19 Peking University China 
20 National University of Singapore (NUS) Singapore 
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A key question relates to the incentives for people to study subjects germane to the needs of the bio-
medical sector.  With respect to the destinations of first degree holders leaving university in 2006/8, 
there is relatively little difference in the percentage going on into employment with first degrees 
in Biology, Physical Sciences, or Engineering & Technology compared to the entire population of 
graduates (see Figure 6.2).  Biology graduates are more likely to go to further study compared to the 
population of graduates, but less so than those with degrees in physical science.  The wage returns 
for scientists (excluding mathematicians) appear to be around the average for all graduates.  The 
data in relation to wages suggests that science graduates tend to earn around the same level as 
social science graduates after being in the labour market for around four years, but less than those 
who graduated in medicine, engineering, or mathematics and computing (Purcell et al., 2005).
These data suggest that the overall level of demand for scientists is no greater than that for all 
graduates, though the evidence suggests that recently qualified graduates enjoy a wage premium 
over their counterparts who are not graduates.  This does not take into consideration qualitative 
differences between graduates.  From the interviews conducted as part of this study and from some 
of the background literature, there are concerns that science graduates are sometimes lacking the 
basic scientific and social skills which companies require (see section 6.4).
Figure 6.2 Destinations of Graduates in Selected Subjects, 2007/8
 
Source: Table 3 - Destinations of full-time UK and Other EU domiciled first degree graduates by subject area of degree and gender, 2007/08, 2006/07 and 
2005/06 - http://www.hesa.ac.uk/dox/fsr137/fsr137_table_3.pdf
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6.3 Supply of Intermediate Level Skills
As indicated elsewhere in this report, the industry as a whole is also dependent upon the supply 
of intermediate level skills.  Evidence suggests that the supply of Apprenticeships is constrained 
in part by the lack of supply of training places provided by employers (HoL, 2007).  But where 
employers do invest in Apprenticeships they can recoup their costs relatively quickly and achieve 
a number of benefits such as: a having a cadre of people from which to select future supervisors 
and managers; or having the values of the firm instilled in the employee from an early age (Hasluck 
et al., 2008).  In relation to the bio-medical sector the two Apprenticeships of particular interest 
are: (a) Engineering; and (b) Chemical, Pharmaceutical, Petro-Chemical Manufacturing & Refining 
Industries, respectively.  In 2007/8, there were 200 new starts (the same as in 2006/07) in the latter 
(the same as in 2006/07),33 and 13,900 in the former (up 2,600 on 2006/07).   Across Engineering 
and Manufacturing Technologies as a whole there were 43,100 new starts in 2006/07 compared to 
34,700 in the previous year.
6.4  Supply from the School System
Many of the critical skill demands employers reported in Section 5 (the demand for skills) were often 
at a graduate and post-graduate level.  It was also evident that a key requirement was a strong 
quantitative knowledge (mathematics and statistics) and a good level of understanding in many 
cases of sciences allied to biological sciences, especially chemistry.  Looking simply at the supply of 
graduates tells only part of the story since there have been a significant number of initiatives launched 
by Government to improve the science and mathematics teaching so that more school pupils will 
achieve GCSEs in the these subjects and potentially go on to study at A-level and beyond. 
Level 5/6 is the level pupils are expected to attain in Mathematics and Science by the age of 14 (Key 
Stage 3).  Figures 6.3a and 6.3b show the percentage of pupils attaining this level in Science and 
Mathematics between 1995 and 2007.  The general trend is for an improvement in the percentage 
achieving this level. Figure 6.4 shows the percentage gaining a grade A to C at GCSE which shows 
a flatter trend. 
33 http://www.thedataservice.org.uk/statistics/sfrjun09
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Figure 6.3a: Percentage of Pupils Attaining Level 5/6 at Key Stage 3 in Science
 
 
Figure 6.3b: Percentage of Pupils Attaining Level 5/6 at Key Stage 3 in Mathematics
 
Source: DCFS 
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Figure 6.4 Percentage of Pupils Achieving Grades A*- C in Mathematics and Selected Science 
GCSEs 1994 - 2007
 
Source: DCFS
Note: Data for 2007 are provisional At KS4 (GCSE)
The National Curriculum allows for two alternative science courses: Double Award Science, which is equivalent to two GCSE subjects; Single Award Science, 
which is equivalent to one GCSE.
 
The data in Figure 6.5 shows the number of enrolments for A-levels in Mathematics and Science over time 
and shows that subjects such as Physics have struggled to reverse the decline in the number of students, 
while Biology appears to have been a relatively popular choice over time.  Overall the evidence suggests 
that the number of people studying Biological Sciences has been relatively strong especially so compared 
to other scientific disciplines, but the evidence from the literature review and interviews with stakeholders 
reveals that employers are looking for a breath of scientific skills, not just those strictly classified to one 
discipline.  In particular, they are looking for strong quantitative skills.
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Figure 6.5 Number of Pupils Entered for Mathematics and Science A-Levels 1997 - 2008
6.5. Qualitative Mismatches
As well as calls for increases in the number of people who are studying degrees related to bio-medical 
sector, there have also been calls for the content of education to be modified in a number of ways. 
This is not just a recent phenomenon but a long-term, continuous campaign for the education sector 
to modify the content of the education and training it provides to meet the needs of the sector.
A key problem, or concern, appears to be how to instill the concept of multi-discipliniarity or the 
ability to function within multi-disciplinary teams, in the education and training individuals receive. 
As one report said: “The concept of disciplines per se may be a stumbling block for progress in 
sciences since all major challenges are multi-disciplinary” (Breimer, 2002).  This report, drawing on 
the research of Triggle and Miller (1999), also revealed that pharmaceutical scientists in future will 
require training which provides them with:
• more scientific breadth to facilitate effective communication with other scientists;
• greater involvement in multidisciplinary research projects to aid better functioning on project teams;
• opportunities to refine written and verbal communication skills;
• greater access to computers/computing networks to better handle the explosion of new information;
• exposure to ethical issues that may be encountered in judgment based on performance;
• experience of industry to assist more intelligent career choices;
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• international exposure to help develop the social and cultural skills needed in a globalised industry;
• Nearly ten years later, these are still some of the key priorities for skill supply for the sector.
There remains, however, a need for people in the pharmaceutical industry to have practical skills as 
the following makes clear:
 “For any area of the pharmaceutical industry… pharmaceutical scientists are needed who can 
problem solve on a foundation of science and practical, technical skills.  The industry needs 
pharmaceutical scientists who can make scientifically sound decisions in a highly competitive 
environment, individuals who are able to separate the “need to know” from the “nice to know” 
without compromising quality.  In relatively smaller, less vertically integrated companies, such 
independent generic companies and start-up biotechnology companies, pharmaceutical scientists 
need to be able to critically evaluate outsourced products…and services as well as handle a 
broad range of responsibilities within the organisation” (Till, 1997, p. 837)
6.6 Meeting Demand
In general, the evidence presented by industry groups suggests that supply is not keeping pace either 
qualitatively or quantitatively with the demands of employers.  For example, a review of the skill needs 
across a variety of disciplines with respect to R&D and manufacturing in pharmaceuticals comments:
 “Having identified the types of career opportunities available to life scientists within pharmaceutical 
R&D, it is then vital to ensure that their education and training provides the requisite skills base. 
From the deficiencies described above, it is clear that this is currently often not the case. There 
are several commonly shared areas of concern across disciplines; 1) a lack of knowledge of the 
basics e.g. chemists who cannot describe what a mole of compound is, or clinicians with little 
knowledge of the principles of clinical trial design, 2) a lack of knowledge as to how to apply 
theory to actual practice e.g. graduates who can only follow a prescribed protocol and do not 
have the skills to develop new methodologies independently and 3) a lack of practical skills e.g. 
in vivo biology and toxicology or the awareness of the types, uses and applications of complex 
technologies.” (Edwards, p. 31).
The ABPI also point out deficiencies they see on the supply side relating to the provision of skills 
(APBI, 2008):
• basic mathematical capability;
• practical skills;
• ability to apply scientific and mathematical knowledge.
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With respect to higher level skills related to the key technological changes in the sector, the 
APBI comments:
 “...higher level critical skills have not yet enjoyed the focus, incentives or funding initiatives 
concomitant with their pivotal importance to key UK initiatives such as translational medicine.  If 
the UK wants to compete in a global environment for Bio-medical research it must take seriously 
the competition in skills supply that is emerging in countries such as China, Singapore and India” 
(ABPI, 2008, p. 5).
Whilst it is important that employers are able to acquire the skills necessary to meet the demands of 
both current and future markets for bio-medical goods and services, it is also important that the industry 
is able to provide career opportunities which prove attractive to would-be recruits.  Where shortages of 
some skills are cited, such as the demand for instrument and process control engineers, the underlying 
cause appears to be relatively high labour turnover in some instances.  It needs to be recognised 
that many of the scientific and engineering skills – alongside the generic skills of management and 
leadership, and numeracy – the industry requires are also in demand in other sectors.
Cogent and SEMTA’s analysis of the mismatches in the biosciences sector indicates that employers 
experience hard-to-fill vacancies across a range of scientific disciplines and technical skills (SEMTA, 2006).
6.7 Conclusion
The quantitative evidence suggests that there has been an increase in eductional attainment in 
mathematics and science over recent years.  If one were looking to identify the key skill shortages 
in the scientific field, it would appear to be in mathematics and computing, and engineering, where 
the wage rates of graduates are relatively high (Purcell et al., 2005).  Employers, however, are not 
complaining so much about the number of applicants so much as the specific skills they possess – it 
is not so much that there is a shortage of pharmacologists per se, rather those who are skilled in, 
say, clinical pharamacology.  To some extent this is inevitable given the pace of change in the sector 
because it takes time for the signals from employers to feed through to the formal education system. 
The key issue is the speed with which the supply side can respond to the signals it receives.
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7.1 Introduction
The literature suggests that they are considerable gains to be obtained from the extent to which, 
on the one hand, companies agglomerate their activities, and on the other, the State encourages 
collaboration between organisations and agencies engaged in R&D activities.  Where this works 
effectively, R&D activity is increased (e.g. spillover effects), and the pool of available skills is similarly 
increased through attracting people into a network or spatial agglomeration, sharing knowledge 
through the network, and potentially lowering the cost of training (via economies of scale).  In summary, 
clustering / networking has the capacity to bring about a higher skill equilibrium or trajectory.  As noted 
elsewhere in this report, there is evidence of clustering in the pharmaceutical / biotechnology sector 
relating to R&D – around Cambridge and the corridor to the west of London – and in manufacturing 
(e.g. in the North West).  There is less evidence of clustering in the medical technologies sector, but 
there is evidence of regional agenices promoting this activity.
The chapter looks at the evidence relating to the agglomerative activities and the benefits this can 
confer on a sector, region, or country; assesses the evidence in relation to the bio-medical sector; and 
uses the West Midlands medical technology cluster as an example of how clustering or networking 
can develop capacity which can make use of the existing skills base.
Before providing national and regionional examples of networking, clustering, or synergy between 
organisations (companies, HEIs, the healthcare system), a brief summary is provided of different 
types of collaborative activities which firms engage in, especially those in R&D intensive sectors 
such as the bio-medical one.
7.2 Collaborative Activity
It is possible to make a distinction between activities in three areas – development, production 
and adoption – for example, the health service can adopt the use of MRI scanners without the UK 
necessarily developing or producing them.  Equally, however, it seems obvious that there should be 
synergies between these three areas that make their associated activities more efficient and more 
dynamic. Potential areas of synergy and gain are manifold, for example:
• collaboration spreads knowledge along the supply chain of development, production and adoption. 
For example, knowledge of health needs and technology gaps that are not currently being met;
• skills produced by universities/university hospitals and the FE system, etc. which may be used in 
or transmitted to one or more of the three areas;
• the procurement activities of the NHS, acting as a stimulus to innovation and quality improvements 
amongst their suppliers and potential suppliers;
• the development of buyer-supplier chains, knowledge networks, quality agreements and regulations; etc.
7 Synergies and Spillovers, Collaboration  
 and Networking, and the National Innovation   
 System (NIS)
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Synergies can arise from “arms-length” relationships; for example, the presence of a high quality higher 
and further education system may result in an abundant supply of skills and knowledge relevant to 
the health system, reducing the need for training within the health sector and lowering the cost of 
employees and, thereby, the cost of the provision of health services.  This group of synergies are 
largely market-orientated – e.g. the presence of a large and dynamic medical technologies sector may 
increase the supply of more advanced technologies to the health sector at a lower price – and largely 
take place through the traditional “input-output mechanism” (Leontief, 1941; Stone, 1947 and 1954).
The potential gains from synergies are likely to be significantly enhanced where the key actors (e.g. in 
development, adoption and production of new technologies) network and collaborate with one another. 
The literature suggests that networking and collaboration are sources of “spillovers” and “externalities”, 
which, in this particular instance, are likely to be significant sources of improvements in the rates of 
technological change, productivity growth and social welfare.  The principal forms of collaborative or 
synerginistic activity that are interest in the context of the bio-medical secor are described below.
• Spillover and Externalities. Spillovers and externalities are perceived as largely non-market 
mechanisms whereby the actions of one organisation postitively (or adversely) affect the activities 
and outcomes of other enterprises.  Spillovers come from the failure of enterprises to appropriate 
all of the benefits that accrue from their activities (see Griliches (1992) (Bosworth, 2009), Nelson 
(1959), and Arrow (1962)).  Spillovers may be technological, spatial, or both;
• Buyer-Supplier Relationships. In the context of the present discussion, buyer-seller relationships 
take on a special importance.  Any form of buyer-supplier relationship, even if short-lived, in some way 
extends the boundaries of the firm. They are a mechanism for the transmission of information flows, 
including new organisational or technological demands.  In addition, buyer and supplier relationships 
form key elements of Porter’s five competitive forces relating to the emergence of sustainable 
competitive advantage (Porter, 1985).  Procurement is one of the support functions (alongside firm 
infrastructure, human resource management and technology development) in the Porter model (op 
cit. p. 48).  Management of the supply chain relationship is, thus, crucial to optimising the value chain 
of the buyer organisation. Oakey’s (1984, pp. 88-90) comparative study of small high technology 
firms in the South East of England, Scotland and the San Francisco Bay area, finds that buyers are 
essentially technologically dependent on their suppliers at each stage of the supply chain;  
• Government Procurement Activity. In the present context, the role of public procurement in the 
innovation process is particularly important because of the size and importance of the NHS.  The 
Government, however, and its various arms and agencies form the largest single “customer” in most 
economies.34 In certain sectors, such as defence and pharmaceuticals, the government (directly or 
at arms length) is probably the single most important influence on the market.  The Government 
can therefore be a force that either depresses or stimulates innovation.  The argument extends 
far beyond government procurement, however, in that there are spillovers between all firms in the 
buyer-supplier chain. If buyers are producing low specification products that sell at a low price, then 
the demands that they place on their suppliers will also tend to be low specification and price;
34 According DTI (2003, p. 82), public sector procurement amounted to £109 billion during 2001-2 – equivalent to about 10 per cent of GDP. By 2008, 
procurement expenditures are reported to have been about £150 billion. http://www.ogc.gov.uk/About_OGC_news_8440.asp.
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• Long-term Contractual Links.Repeat orders and other long-term contractual relationships are 
a potentially important element of the organisation’s intellectual capital (Brooking, 1997; Lynn, 
1998).  The contract itself is likely to be based on the formal product or service specifications 
prepared by the technical department of at least the buyer, but possibly both the buyer and 
supplier. A long-term contractual relationship can be distinguished from a long term contract, as 
in the former, even where contract lengths are relatively short, both firms expect the contract to 
be renewed (Ferguson, et al. 1993, p. 24). In the discussion of complex products and services it 
is clear that the continuing nature of the invention, innovation and design processes during the 
period of production, would entail ongoing discussions between the supplier and the buyer;
• Research Joint Ventures (RJVs). These involve two or more separate companies and are 
defined as:
 “… arrangements in which some firms agree to share the expenditures and the benefits associated 
with a given research project.” (Tirole, 1990, p. 413)
 According to Kang and Sakai (2000, p. 33) the extent of international collaboration over the invention 
process more than doubled over the period 1980 to 1995.  They report that the share of patents in 
OECD countries that involve two or more inventors based in different countries rose from 2.1 to 4.7 
per cent over this 15 year period. Strategic R&D alliances tend to be concentrated in knowledge-
based sectors, such as biotechnology, pharmaceuticals and ICTs (Kang and Sakai, 2000, p. 33)
 The literature on RJVs emphasises two principal factors:
 i. by bringing firms together, it is possible to internalise the benefits of the R&D amongst the 
 participant companies. Where the firms act independently, spillovers occur that give rise to a 
 free-rider problem, which reduces the private incentives to conduct R&D;
 ii. related to the previous point, RJVs result in cost savings because the costs of any given R&D 
 project are shared (Röller, et al. 1997).
How all of the above might operate in a national and regional context is outlined below.
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7.3 National Innovations Systems and Policy Intervention 
The gains from “joined up” private strategies, public policies, with networking and collaboration (both 
domestically, across the different areas, and internationally), appear likely to improve the dynamism 
of the innovation system in meeting both health care needs and in the generation of domestic 
employment in the sectors supplying products and services to the health sector.
In the literature on the development of a critical mass of bio-medical activity there is considerable 
attention given to clusters or geographical agglomerations of companies.  These often develop out of 
specific sets of historical circumstances so are not always readily replicated; for example, the cluster 
of IT companies in Northern California stems from the needs of the US military in the 1950s, the 
existence of military facilities in the area, the cheap availability of land, and the proximity of several 
universities and their research staffs (Finegold, 1999).
Clusters are normally viewed as “… geographically proximate groups of interconnected companies, 
suppliers, service provides, and associated institutions in a particular field, linked by commonalities 
and complementarities” (Porter and Ketels, 2003).  According to Porter and Ketels, clusters generally 
influence competitiveness in three main ways:
i. by increasing the level of productivity at which constituent firms can operate (i.e. carrying 
 lower levels of stock due to local suppliers, reduce downtime because of access to local service 
 providers, etc.);
ii. by increasing the capacity for innovation and, thereby, productivity growth;
iii. enable new business formation, which further enhances innovation (i.e. via the presence 
 of experienced researchers, access to specialized venture capital, legal services, etc.).
With respect to the bio-medical sector, the Boston Life Sciences Cluster which includes “… world-
class research universities, teaching hospitals, competing biotech companies, and cluster institutions 
that facilitate interaction among all these” is perhaps the most well known and successful (see Figure 
7.1).  It certainly has the hallmarks of a high-skill ecosystem (Finegold, 1999).
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Figure 7.1 Boston Life Sciences Cluster
 
Source: Porter and Ketels (2003, p. 28).
Note: Employment numbers for 2000 given inside boxes when available.
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It is clear that some clusters have grown organically because the institutional, economic and social 
framework was conducive to their formation and success, but the picture is not all positive, particularly with 
regard to the possibility of artificially creating the “culture” in which a cluster will develop and flourish.  
Across Europe there are key clusters or agglomerations in the bio-medical sector, such as in 
Cambridge in the UK, Bavaria and Baden Württemberg (in Germany) and Medicon Valley (in 
Denmark) which share, to differing degrees, the characteristics of the Boston Life Sciences model. 
There are common features to these clusters or agglomerations which mainly hinges on the State 
policies which are designed to bring about the quick transfer of technology into the health care 
system with the State acting to bring companies and researchers together to promote research and 
successful product innovations.  The agglomerations, to some extent, have developed organically 
and have been dependent upon the existence of key companies.  In Bavaria, this relates very 
much to the location of Siemens Medical, and in Medicon Valley, presence of four fully integrated 
pharmaceutical companies (Novo Nordisk, AstraZeneca, H. Lundbeck and LEO Pharma), which 
attract highly qualified employees to the region (Vogler Ludwig, 2004; Thomsen, 2004).  Similarly in 
Cambridge the university has been a hub of activity around which developments could take place.
The evidence from the UK suggests that there are concentrations, agglomerations, and clusters 
relating to the bio-medical sector, such as those which surround Oxford and Cambridge, and which 
exhibit many of the features of clusters found in Massachusetts, Denmark, and Germany which 
have also developed organically over time.  Fostering links between the HE sector and industry, 
however, is not without difficulties as documented in the Lambert Review of Business – University 
collaboration (Lambert, 2003).
To show how agglomerative activity can develop – and the various facilitators and inhibitors – and 
the role of skills in this development, a case study of the West Midlands medical technology cluster 
is provided.
7.4	 Case	Study:	Diversification	into	Medical	Technologies	in	the	West	Midlands
Ten years ago in the West Midlands, a number of the public bodies with economic development 
arms were becoming increasingly concerned about the vulnerability of manufacturing sectors in 
general and several regionally based big companies in particular, not least in automotive.  Medical 
and healthcare technologies were identified at regional and sub regional levels as a sector with 
significant growth opportunities given ageing populations, lack of technology in the NHS and the 
strength of OEM and supply chain companies in the region with the innovation and engineering skills 
to potentially be able to diversify their activities and address such opportunities.
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Unlike other opportunities for SMEs, it was recognised at that stage that while there were mass 
market opportunities, there were also a multitude of niche opportunities in medical technologies and 
that the formalised hierarchical supplier tier structures typifying automotive and aerospace did not 
exist for many products, offering much greater potential freedom to a SME to be able to develop and 
exploit its own IP.  Equally, the many barriers in the sector for SMEs were also recognised including 
the regulatory issues and the difficulties with routes to market and the many decision influencers.
The Regional Development Agency, Advantage West Midlands, encouraged a company led cluster 
to develop around medical and healthcare technologies and in similar timeframe, Medilink West 
Midlands was set up as a trade association to support SMEs in the region with healthcare technology 
interests under “franchise” from the originating Sheffield body.  At almost the same time, some 
of the available ERDF resources in the region were used to support a £6m University led Health 
Tech programme to help SME companies with the many change management issues including the 
regulations and barriers to diversifying their businesses.
Skill sets were, are and continue to be a major issue in this scenario.  SMEs are often owner managed 
and have originated from a variety of origins, but with the possible exception of family succession, 
rarely exist without considerable trauma for the owner who has had to be very determined to achieve 
success.  In some cases, a larger company background may have provided the MD with the strategic 
thinking skills and competences to address the major company structure shifts and the different style 
of business operation required in the healthcare technologies sector but in most cases this is not the 
case and the first barrier to successful strategic change is the MD.
Given an enlightened, or open to change MD, the engineering capacity in such businesses is often 
strong and innovative but rarely structured to appreciate the level of evidence and development 
required in health care systems by the many decision makers and takers or the long timescales 
involved – particularly in the English system.  In many cases SME companies set up a completely 
separate business, not just to distance the business risk, but to enable a completely different style of 
customised engineering with a supporting public face that relates to the expectations of the healthcare 
sector.  That said, the engineering competences in the business can often adapt and bring significant 
levels of innovation into the medical technology sector by transferring their knowledge of materials, 
functions and devices from other sectors.  But there still does need to be one or two engineering 
leaders with the flair for different functionality and design parameters in medical technologies.
The length of curve to develop manufacturing operations can be similarly long and protracted but there 
are many advantages in low volume niche markets to keeping this function in close proximity to the 
engineering and the development processes involved.  Low labour cost is most unlikely to be a significant 
differentiator for a business in such markets, particularly if only available at a distance and in a different 
culture.  Problem solving is likely to be the more important skill – not least in working with manufacturing 
systems that typically need to be far more agile, and more flexible, than for other sectors.
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The complexity of the healthcare market has posed the largest set of difficulties facing diversifying 
SMEs – particularly those that were originally structured to operate in a matured, tiered supply chain, 
large OEM dominated sector.  Thoroughly understanding the market and its decision structures is vital 
to the success of very different, and often extended, investment return models and the profitability 
of the business.  There is also a major onus on the marketing leader to ensure that the very different 
business model required is understood by the rest of the managers in the team.  There are a number 
of ways in which SMEs can and have acquired, or developed, these competencies but very few 
began diversification with this level of capacity in house.
Researching the SIC codes 10 years ago for designers or companies manufacturing medical 
technologies in the West Midlands revealed a grand total of six companies.  This figure of course 
completely under represented the true picture as even then there were a significant number of 
companies who had a percentage of their activity in healthcare technologies but that was either 
not their main activity or their medical activity was classified under a different generic heading. 
Today, the clustering activity now reveals more than 1500 companies in the region with interests and 
activities in healthcare technologies, again most are not 100 per cent medical technologies.
The examples below illustrate how companies have developed within the cluster and how their skill 
needs have developed (see Boxes 7.1 and 7.2)
Box 7.1 Emerging Skill Needs in a Medical Technology Engineering Company
Electrical Equipment Company
Some six years ago a West Midlands company engineering and manufacturing electrical equipment 
took advantage of the Health Tech programme to look at some of the opportunities and issues 
involved in the healthcare technologies sector with a view to potentially expanding into that market. 
At that stage they had tried a couple of product ideas for people but had no level of regular sales or 
focus for those ideas in healthcare.  In December 2008, when recession was biting hard, a review 
meeting was help with the MD:  “Six years ago, we were 80/90 per cent automotive or general 
engineering, today we are 80/90 per cent healthcare technologies.  We haven’t had a single order 
from automotive or our traditional markets for the last two months and if we hadn’t diversified into 
medical we wouldn’t be having this meeting today - because I wouldn’t be here”.
In November 2009, a further meeting revealed the continuing difficulties for the business in other 
sectors but that the healthcare sector was going from strength to strength and the company was 
in the middle of introducing new products for the healthcare market based on novel electronic 
components.  Pressures on the business have been heavy, not least on the MD and the degree 
of change that he has had to accommodate as leader of the engineering and marketing effort; 
new skills and technologies have had to be acquired in the electronics field but many of the other 
business processes have been able to diversify through adaptation.
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Box 7.2 Emerging Skill Needs in an Assistive Technology Company
Assistive Technologies Company
Many SME’s have developed successful niches in healthcare technologies based solely on transfer 
of existing knowledge from other sectors but the opportunities that are presented by a rapidly 
developing sector such as healthcare are rich for innovation from a wider, and multiple sets of skills, 
competences and ideas.  Already the region is seeing examples of companies achieving this.  A 
manufacturer of assistive devices for the elderly began, and has very successfully grown the business 
largely based on stand-alone electrical and mechanical equipment.  The company is now introducing 
electronic sensors and communication systems which will not only be able in the future to provide 
remote data on the functioning of the equipment, but will also be able to provide a communication 
platform for data related to the personal health and functioning of the equipment user.  In this case, 
it is an excellent example of developing skill sets for short term pragmatic opportunities relating to 
the equipment functionality whilst at the same time putting in place flexible strategic skill sets and 
technology platforms that can deliver healthcare functionality to any of the potential private or public 
healthcare communication networks that will unfold in due course.
Diversifying into health care is not without its difficulties and the example of the West Midlands 
engineering companies suggests that negotiating access to the NHS procurement system – and that 
of other countries – is complex.  
An important element of the West Midlands approach is to engage the region’s HE sector in the 
development of medical technologies.  In the West Midlands region there are nine Universities with 
research and other interests in medical and healthcare technologies; some with medical schools, 
some with health faculties of various types and some with medical engineering or related digital and 
software technologies.  Over the last 18 months a group has come together under the title of Medical 
Interchange to represent their interests in increasing collaboration with other partners, typically in 
industry, in order to reduce the time to commercialise good ideas and to produce patient benefits 
and better healthcare economics more quickly.  A key mechanism to achieve this is the use of trade 
sector events and expositions in order to promote University research, capability and innovation and 
to attract industrial partners to collaboration opportunities.
The company examples cited above focus on companies that offer the potential for significant 
numbers of jobs that can be created through conversion and adaption from the existing skills base 
in traditional engineering and manufacturing.  As such, there are and have been strong clusters in 
product areas such as automotive and aerospace but also in a number of component technologies 
that are more generic and can be readily adapted to healthcare products including tooling and 
instrumentation, automation & robotic technologies, information & communication technologies.
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Alongside such job opportunities, there is also growth in the West Midlands, as there is elsewhere, 
in companies and jobs related to genomic and bio database analysis and the provision of testing and 
a range of other similar services to the healthcare, research and knowledge based sector.  In this 
context there are a number “hot spots” of knowledge that are strong in the West Midlands including 
software, media and related interactive technologies.  Some 10 per cent of the world market for such 
interactive software originates in the West Midlands with much of the software traditionally being 
supplied to Sony, Warner and other big groups under sub contract for big budget entertainment films, 
computer games and other media.  In more recent years the complexity of these projects has enabled 
the English companies to retain their own IP on the modules that they have been supplying.  In turn 
they have been able to capitalise on this IP in the strategic use of this software for the development 
of Serious Games techniques – i.e. interactive software for training, simulation and predictive or 
forecasting scenarios for practical decision trees and the development of strategic planning.  In this 
context the defence sector has now become one of the largest users of such software in the last 
few years but is rapidly being followed by the health sector where the potential life (or otherwise) 
outcomes can be equally concerning.
Programming and software skills are clearly a major requirement in relation to the development of the core 
processes and modules of a Serious Game and will continue to be so in healthcare applications.  All the 
NHS teaching hospitals are potential customers for such software in their own training and development 
programmes and that all the clinicians are faced with similar issues such as: how do you realistically 
train a student in a surgical procedure which may only occur a handful of times during his or her career? 
The answer, in part at least, is to use Serious Games applications.  Hence there is growing interest in 
the region from various agencies to apply Serious Games applications into the health sector.  Again this 
raises skill issues in relation to being able to develop a product away from its initial purpose and gain 
entry into a system which has its own complex product licensing and product procurement rules.
7.5 Conclusion
There is a wealth of economic evidence to reveal the benefits which derive from spatially concentrated 
networks of companies, research and development centres, and State agencies.  These benefits relate 
to increases in R&D activity, increased skill levels, and employment growth.  The pharmaceutical and 
biotechnology sector provides examples of how has been successfully developed across Europe and 
North America.  The West Midlands case study is provided as an example of how this type of approach 
can be developed in the medical technologies sub-sector through persuading engineering companies to 
diversify their activities into health care operations.  With respect to the number of engineering companies 
now engaged in health care – even if this is not their primary market – there is prima facie evidence of 
success.  Moreover the region provides evidence of positive spillovers given the potential for the serious 
games sector in the region to develop its applications for the health care market.  What is apparent from 
the case study of the region is the need for concerted action between a range of regional partners to 
push the diversification agenda and then support its implementation.  The principal skill needs which 
emerges is that of being able to access the procurement systems of the health service – either in the UK 
or abroad – and then meet the demanding product standard requirements.
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What is less clear from the evidence which relates to a more embryonic cluster of activity is the extent 
to which long-term relationships are established between organisations of the following types:
i. intra-firm supplier – buyer relationships;
ii. industry-HEI-healthcare collaboration; or
iii. RJVs.
These are likely to be well established in more mature clusters of activity – such as the Boston Life 
Sciences cluster or the more established ones in England – but would appear to be dependent 
upon strategic intervention from public agencies to bring about their effective operation (e.g. through 
efficient information flows between organisations) where they are less well established.
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8.1 The Sector
The bio-medical industry is one of strategic importance in relation to the nation’s economic and 
physical well being.  The global market for pharmaceuticals and medical equipment is huge and 
is likely to grow with the emergence, amongst other things, of new regenerative and preventative 
therapies, the convergence of pharmaceutical and medical technologies, and the use of information 
communication technologies allied to health care.  All nations in the western world are investing 
heavily into this area of activity, and it is apparent that developing countries are also building a critical 
mass of expertise.
Several features of the bio-medical sector make it particularly important; not least is the likely strength 
of future demand for outputs of this sector.  For example, increased levels of demand are likely to be 
driven by a wide range of factors, including the increasing need to: 
• control the spread of diseases in an increasingly global economy; 
• develop preventative therapies to keep individuals economically activity and in employment;
• meet the health needs of an aging and growing population;
• reduce energy consumption and waste; 
• ensure that existing best practice is rapidly disseminated across the population in need, coupled 
with equality in access and treatment; 
• meet the demand for more “bespoke” treatments.
The sector is one of the few remaining, relatively strong bastions of manufacturing in the UK.  It is 
an important exporter of goods and, a number of the sub-sectors, such as the medical technologies 
sector, are net exporters of goods.  Given the growth in future demand likely to be experienced by 
health providers, there is the opportunity for a significant proportion of the supply of bio-medical 
products which are used in health provision to be domestically produced, rather than imported.
The sector is diverse and is not easily categorised within the Standard Industrial Classification. 
Recent trends in and future opportunities for growth and employment are heterogeneous across 
different areas of activity within the sector.  These areas seem likely, therefore, to require different 
policy approaches if they are to maximise the benefits that they offer to the UK economy.  The key 
issues are how to sustain production in the more mature sectors which seem likely to be subject to 
pressures leading to contraction and to identify and provide appropriate policy support for areas where 
there is the potential for future growth.  To this end, the Office for Life Sciences was established within 
the Department for Business Innovation and Skills in January 2009 to provide targeted intervention 
to help the sector realise its potential.
8 Conclusion
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Part of this diversity stems from the fact that the bio-medical sector has been experiencing a period 
of major change and upheaval that has led to increased uncertainty about its future.  Some of this 
change and uncertainty has been less than positive, such as:
• the decrease in the ratio of new products coming to market relative to investments in R&D in 
certain key areas, such as pharmaceuticals;
• the sorting-out and removal of relatively high risk, uncertain return activities caused by the bursting 
of the “dot-com bubble”;
• the effects of economic slowdown, increased pressures to reduce costs and lower prices, associated 
with the need to outsource, network and/or strategically relocate different functions globally.
Conversely, other aspects of change and uncertainty give rise to new opportunities, although, 
admittedly challenging opportunities.  These primarily, though not exclusively, stem from the 
enormously rapid rates of technological change in areas relevant to health, such as:
• the shift from chemical to biological based pharmaceuticals and the greater use of biomaterials;
• the rise of new technologies that enable existing functions, such as R&D or initial drug-testing to 
be carried out in entirely new ways;
• the rise of diversely different new technologies such as stem cell research, diagnostic techniques, 
medical equipment for use in the “home” rather than the hospital, etc. open entirely new avenues of 
treatment, change the balance between prevention and treatment, the location of treatment etc.
In much the same way that bio-medicine spans different sectors, today, different strands of bio-
medicine span different areas of technology and the disciplines needed to be competent in them.
The detailed analysis of the patent data suggests that the extent of technological opportunities varies 
enormously by area of technology.  Nevertheless, being at the forefront of technology is not enough, 
as there is an enormous degree of international competition to be involved with the bio-medical area. 
As noted earlier, there are few major industrial countries that have not developed a cluster of bio-
medical activity, which is typically based around company – HEI collaboration and partnership.
Rather than discuss existing technologies and their continuing importance or the emergence of new 
technologies and the opportunity each offers, the discussion turns to two stylised example “sectors” 
which appear, at the present time, to be quite different, require different policies and support, and 
to meet the UK’s needs in quite different ways.  These example sectors are pharmaceuticals and 
medical technologies.
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The first of these is the pharmaceuticals sector, which is an example of a relatively mature, R&D 
intensive technology which has been driven forward by advances in the science base, but is now 
threatened, at least in its more traditional lines of approach, by a rising difficulty of isolating effective 
new products per unit of R&D effort.
Historically, this area of activity has been driven forward by the employment of the most highly skilled 
individuals.  Estimated employment is c73,000 and forecast to be static over the decade to 2020. 
As a generalisation, this part of the bio-medical sector not only places pressure on the supply of the 
very highest STEM skills by the public sector, has been able to attract the best talent to the UK from 
many parts of the globe and has contributed itself to the education, training and experience of staff 
at the highest level.
The trends in patent applications suggest that this area is far from exhausted, but, equally, there 
are other omens that suggest that this line of approach to health problems may be overtaken by 
other areas.  If the latter is correct, then there is a need for government policy to assist this sector to 
sustain its high level activities for as long as possible.  It should be noted that, even in a worst case 
scenario, existing patent protection for many of the pharmaceuticals will continue for the foreseeable 
future and subsequent generic production can still be profitable.  However, a decline in this sector, 
given its work at the frontiers of science and its generally high skills demand, would have important 
implications for UK performance. The rise of biotechnology, however, provides the pharmaceutical 
sector with a substantial opportunity to develop the next generation of products.
The second sector concerns that of medical technologies.  Employment levels are less precise 
here and estimated to be in the range of 40-60,000 depending on the source, with BIS/UKTI/DoH 
estimating 52,000, but are forecast to decline slowly.  The upsurge in patent activity in this sector 
was perhaps more surprising, and not all of it was associated with the high-technology end of the 
spectrum such as diagnostic technologies (e.g. scanners).  Some of the areas of technology where 
organisations were still actively patenting might be considered as being at the lower end of the 
technology spectrum (e.g. bandages and dressings).
Production based upon these technologies still has the potential to create employment for large 
numbers of individuals and, in particular, those down the skill spectrum.  What is interesting is that a 
number of the component areas of medical technology, appear to require skills that may be available 
in more abundance (e.g. electrical, engineering and electrical-engineering skills), and a growth in this 
area might be able to off-set a decline in more traditional manufacturing areas, such as automotive 
production in the West Midlands.
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8.2 Skill Needs
Analysis of patent data reveals the extent of research and development activity taking place in the bio-
medical field.  It also reveals; the importance of the USA relative to that of either Japan or the European 
Union; Japan’s focus on IT developments, and; the sensitivity of the patenting activity to the economic 
cycle and the extent to which events such as the dot com bubble can have a negative impact on 
innovation and patenting presumably by limiting the availability of capital, especially venture capital, to 
fund innovation.  A point made elsewhere in this report refers to the importance of SMEs in generating 
new ideas and prototypes which the larger corporations then acquire if these look as if they will result 
in a product coming to market.  The impact of the recent tightening of the credit supply may have long 
run implications for innovation in the sector the effects of which only time will tell.
At the current point in time England is well placed to take advantage of future opportunities.  This stems 
from the country’s existing strong base in pharmaceuticals though less so in medical technologies 
where it lags behind both Germany and the USA.  The strength of England’s position results from its 
knowledge base – the supply of highly educated research scientists operating at the cutting edge of 
scientific endeavour.  While the large corporations are significant investors in R&D and associated 
education and training, at least part of the country’s enviable position is a consequence of a strong 
HE base with several universities regarded as amongst the very best in the world in several of 
the scientific disciplines germane the bio-medical industry.  Ultimately the future of the knowledge-
intensive sector of the industry is dependent upon the capacity and capability of the HE sector.
From a labour market and skills perspective there is also a need to consider the potential for the 
industry to create a large volume of employment in addition to the research scientists.   In the UK it 
is estimated that around 110,000 people are employed in the Bio-medical sector, of which around 
95,000 are employed in England and this, according to the Working Futures projections produced 
for this study, will remain more or less stable albeit with some modest reduction in numbers over 
the medium term.  But there are challenges which may result in deviation away from this baseline 
projection.  These can be summarised as such:
• mass manufacture of basic pharmaceuticals, especially those which are out of patent, becomes 
increasingly transferred abroad as pharmaceutical companies attempt to reign in costs in part 
because of the escalating costs of developing new products;
• niche manufacture comes more to the fore in pharmaceuticals as therapies become more bespoke 
and, accordingly do not require large volume manufacture.
The extent to which the latter can compensate for the former is a moot point and it is apparent that 
large scale manufacture is not that mobile.  A switch from the mass manufacture of products to 
niche production has implications for skills – especially at the shop floor level - insofar as the latter 
is likely to be relatively skill intensive and less amenable to automation.  It also has implications for 
investments in training if niche production is concentrated amongst SMEs, given the particular set of 
barriers they face when it comes to engaging in training.
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It is unlikely that there will be a simple switch from one form of production to the other but the extent to 
which there is will result in differing types of skill need emerging.  Both forms of production, however, 
are relatively reliant upon skilled trades workers (typically qualified to Level 3).  The extent to which 
there is a large volume of employment engaged in the manufacture of bio-medical goods is dependent 
upon the supply of skills and strategic choices made by the principal companies in the market. 
The medical technologies sub-sector has received relatively little attention compared to 
pharmaceuticals and biotechnology, in part because it is smaller and often concerned with the 
production of more mature products.  The analysis of patent data, however, suggests that this is an 
area in which there is, globally, a large volume of innovative activity taking place.  Germany and the 
USA are the principal players in this market.  But has noted above there is considerable potential for 
producers in the automotive sector to diversify into medical technologies.
The future skill needs of the sector relate very much to:
• skills required by the R&D process (e.g.. highly qualified scientists able to translate scientific 
breakthroughs into products);
• the production process (e.g. engineers, technicians, and operatives);
• management (e.g. developing and managing inter-disciplinary teams, being able to diversify the 
product range, managing mature product ranges, etc.).
Many of the skills which the bio-medical sector will increasingly require are ones which are typically 
in short-supply across the economy (e.g. generic skills related to management and leadership, 
highly qualified scientists and engineers working at the cutting edge of product development).  As 
noted elsewhere in this report, the nature of skill demand in the sector is such that supply will always 
struggle to keep pace.  There are, however, a range of more commonplace skills which the sector is 
currently dependent upon and will continue to be over the period to 2020.  These include a range of 
engineering and technician roles related to the production of everyday products and operatives who 
work on assembly lines.
In summary, Table 8.1 provides information about the industry’s skill needs over the medium term. 
Without a strong supply of these skills it is likely that output will be constrained.  But as noted 
throughout this report the supply of skills is not sufficient in itself to safeguard a large volume of 
employment engaged in manufacturing.  This relates very much to the strategic choices which the 
large corporations make and the extent to which the networks, clusters, partnering and joint ventures 
of which they are part are concentrated in England rather than elsewhere.   Nevertheless, skills 
supply is part of the overall attraction of England to producers and will influence the emergence of 
networks and clusters.
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Table 8.1 Summary of Emerging Skill Needs
Skill Level Type of skill required Comments 
Technical	/	Scientific	
Skills 
Ultra high Level Skill 
Needs
Post-graduate scientists in a range of 
biological and physical sciences
Generally required in small numbers with highly specialist 
skills, but critical to the future of the industry in England 
High level skill needs Graduate level scientists Better laboratory skills
Improved overall scientific and mathematical literacy 
IT Skills: Graduate level Needed to develop improved communication between 
people and devices – a general requirement for the 
industry over the medium term 
Statisticians and mathematicians: 
Graduate and postgraduate  level 
Processing of data / use of simulation models, etc. 
Engineering Nanotechnology skills, design and  use of new materials 
/ biomaterials ; software /IT – alongside the existing 
demand for chemical engineers, etc. 
Economists: Graduate level Required to assess the cost-benefit of any new 
development and its application to the health care system 
Intermediate level skills Graduate / Level 3 Apprenticeship Skills Required to support manufacturing process.  Especially 
important in niche production if the future of the 
manufacturing sector is based on this form of production
Operative / Assembly 
line skills
Typically at Level 2 Skills at Level 2 are typically employed in the production 
of a range of bio-medical goods.  A shift to more niche 
production is likely to limit the capacity of automation to 
replace these jobs.  Though are at potential risk of being 
transferred to lower labour cost countries. 
Generic Skills 
Management and 
leadership
Graduate level Managing across multi-disciplinary teams 
Managing across organisations, networks, etc…where 
outsourcing used 
Procurement skills / negotiating with health care systems 
All All levels Improved levels of scientific and mathematical literacy.  
Quantitative skills.
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A series of interviews were held with key stakeholders in order to obtain an insider’s views of 
developments in the sector (see Table A1.1).
Table A1.1 Interviews with Key Stakeholders
 
Appendix 1: Interviews with key stakeholders
Type of organisation Number of interviews 
Government regional development agencies 1 
NHS Trusts 1 
Industry – health system liaison bodies 2 
Trade organisations in healthcare 1 
Industry representative bodies 1 
Medical device companies 3 
Pharmaceutical companies 2 
Higher education institutions 2 
Sector Skills Councils 2
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Some care needs to be taken with the interpretation of, and comparisons undertaken using, patent 
statistics (see Bosworth, 1986).  For example, in the present exercise, patent statistics are drawn 
from a number of sources (based upon different jurisdictions – such as the US Patent and Trademark 
Office, the European Patent Office and the Japanese Patent Office.  In addition, different sources 
compile their statistics in somewhat different ways – such as the OECD, which has its own definition 
of the biotechnology sector, which may not correspond identically that that used by other institutions, 
such as the SSCs, including Cogent.
The data reported in the present section were taken from two main sources:
• the OECD publications of patenting activity that form a part of their Science and Technology 
Indicators (STI) database;
• interrogation of individual patent data from the European Patent Office (EPO) ESpace database.
In the present exercise, all of the statistics reported in this Chapter are taken from the OECD 
database.  However, the OECD data are only available up to a certain degree of disaggregation (e.g. 
the first four digits of the IPC).  Hence, EPO data were used in the present report for two purposes: 
first to obtain a greater degree of technological disaggregation (which has been used qualitatively in 
reporting the results) and, second, to ensure that the patent trends from OECD sources correspond 
broadly with those from the ESpace database.
Given that ESpace contains worldwide information for over 60 million patent documents, a number 
of choices have to be made in the method of search, even bearing in mind that the international 
patent classes of interest only form a reasonably small proportion of the total.  To simplify the search, 
the chosen starting point was to examine patenting application activity and, in the case of detailed 
interrogation of individual data, the focus was on applications to the USPTO.1  
Here information is not only available about detailed areas of technology, it is, in principle, possible to 
recombine this information to explore the “technology platforms” that those operating within the sector 
(including the SSCs) recognise and believe to be important when examining future developments 
(see Appendix 3).  In addition, other patent statistics contain other strategic information about 
countries (and, in principle, companies) that give some clue as the extent to which the UK can or 
should position itself as a leader or follower in different areas of technology.  At present, this work is 
in progress and is not discussed in the present report.
Finally, certain areas of activity are much closer to the science base and might be more accurately tracked 
using information about scientific publications and the Science Citations Index (SCI).  While exploratory 
work has been carried out in these sources, it is too early to publish results from this analysis.
 
Appendix 2: Patent statistics - a note
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The technology platforms that Cogent and Semta appear to be currently working with include the 
biotechnology platforms that sit across the sectors:
1. Genomics  
 Genomics as “the study and modification of genetic materials.” Subject matter classified within 
genomics includes: pharmacogenomics, genetic medicines; gene therapy; gene probes; genetic 
engineering; DNA/RNA sequencing; gene libraries; genetic material/genes; gene expression 
profiling and the use of antisense technology.
2. Proteomics 
 Defined proteomics as “the analysis of the expression, localization, functions, and interactions 
of the proteins produced by the genes of an organism.”  Subject areas classified as following 
within the field of proteomics include: proteins, peptides and enzymes; the isolation, purification, 
synthesis and sequencing of thereof; medicines containing proteins, peptides and enzymes; 
peptide/protein libraries; testing with enzymes; and biomarkers.
3. Metabolics (cell function)
4. Bioinformatics 
 Defined bioinformatics to include the “construction of databases on genomes, protein sequences; 
modelling complex biological processes, including systems biology.” The subject areas have been 
classified within this area include: libraries/databases with genetic information, genomes, genes 
and protein sequences and computer modelling of biological and chemical processes.
5. Synthetic Biology.  
 Synthetic biology defined to include the redesign of biosystems, artificial genomes, regenerative 
and synthesis of bioparts.  Subject areas classified as following under synthetic biology include: 
prosthesis; artificial hearts; artificial kidney; cell lines and tissues. 
6. Biotechnology 
 The term biotechnology has been construed narrowly to include health related aspects of life 
sciences that isn’t part of the above categories.  Subject matter classified within biotechnology 
includes: cell/tissue culture; tissue engineering; analysis of biological material; measuring or testing 
involving micro-organism or enzymes; vaccine/immune stimulants/antibodies; micro-organisms; 
and hormones & steroids.
Appendix 3: Technology Platforms
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These platforms can variously combine and lead to the following applications in health:
1. Therapeutics (new biopharmaceuticals produced in part or in whole by organisms, tissue 
engineering, stem cells, vaccines)
 Subject areas that classified under therapeutics include: genetic medicines; gene therapy; 
vaccines; medicines with proteins, peptides or enzymes; cell lines and tissues.
2. Pharmacogenetics (gene drug interactions combined with diagnostics and informatics to target 
ethnic and individual target groups for treatment)
 Subject areas that classified under pharmacogenetics include: genetic medicines/gene therapy; 
gene probes; gene libraries and gene expression profiling.
3. Diagnostics (in vivo and in vitro including genetic testing and biomarkers)
 Areas that categorized under diagnostics include: biomarkers; gene expression profiling & gene libraries; 
analyzing biological material; and measuring and testing involving micro-organism or enzymes .
4. Medical technologies
 Areas categorized under medical technologies include: prosthesis; artificial hearts and artificial 
kidneys.  More traditional medical technologies have been classified under medical technology.
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